<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article xml:lang="EN" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Cancer Immunol Immunother</journal-id><journal-title>Cancer Immunology, Immunotherapy </journal-title><issn pub-type="ppub">0340-7004</issn><issn pub-type="epub">1432-0851</issn><publisher><publisher-name>Springer-Verlag</publisher-name><publisher-loc>Berlin/Heidelberg</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">19655140</article-id><article-id pub-id-type="pmc">2776939</article-id><article-id pub-id-type="publisher-id">739</article-id><article-id pub-id-type="doi">10.1007/s00262-009-0739-y</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Loci controlling lymphocyte production of interferon &#x003b3; after alloantigen stimulation in vitro and their co-localization with genes controlling lymphocyte infiltration of tumors and tumor susceptibility</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Lipoldov&#x000e1;</surname><given-names>Marie</given-names></name><address><phone>+420-241063243</phone><fax>+420-224310955</fax><email>lipoldova@img.cas.cz</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Havelkov&#x000e1;</surname><given-names>Helena</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Badalov&#x000e1;</surname><given-names>Jana</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Vojt&#x000ed;&#x00161;kov&#x000e1;</surname><given-names>Jarmila</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Quan</surname><given-names>Lei</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Krulov&#x000e1;</surname><given-names>Magdal&#x000e9;na</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sohrabi</surname><given-names>Yahya</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Stassen</surname><given-names>Alphons P.</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Demant</surname><given-names>Peter</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><aff id="Aff1"><label>1</label>Department of Molecular and Cellular Immunology, Institute of Molecular Genetics, Academy of Sciences of the Czech Republic, V&#x000ed;de&#x00148;sk&#x000e1; 1083, 14220 Prague 4, Czech Republic </aff><aff id="Aff2"><label>2</label>Institute of Care for Mother and Child, Podolske Nabrezi 157, 14700 Prague 4, Czech Republic </aff><aff id="Aff3"><label>3</label>Department of Molecular and Cellular Biology, Roswell Park Cancer Institute, Buffalo, NY 14263 USA </aff><aff id="Aff4"><label>4</label>Department of Genetics and Cell Biology, Maastricht University, Maastricht, The Netherlands </aff></contrib-group><pub-date pub-type="epub"><day>5</day><month>8</month><year>2009</year></pub-date><pub-date pub-type="ppub"><month>2</month><year>2010</year></pub-date><volume>59</volume><issue>2</issue><fpage>203</fpage><lpage>213</lpage><history><date date-type="received"><day>5</day><month>2</month><year>2009</year></date><date date-type="accepted"><day>2</day><month>7</month><year>2009</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2009</copyright-statement></permissions><abstract xml:lang="EN"><p>Low infiltration of lymphocytes into cancers is associated with poor prognosis, but the reasons why some patients exhibit a low and others a high infiltration of tumors are unknown. Previously we mapped four loci (<italic>Lynf1&#x02013;Lynf4</italic>) controlling lymphocyte infiltration of mouse lung tumors. These loci do not encode any of the molecules that are involved in traffic of lymphocytes. Here we report a genetic relationship between these loci and the control of production of IFN&#x003b3; in allogeneic mixed lymphocyte cultures (MLC). We found that IFN&#x003b3; production by lymphocytes of O20/A mice is lower than by lymphocytes of OcB-9/Dem mice (both <italic>H2</italic><sup><italic>pz</italic></sup>) stimulated in MLC by irradiated splenocytes of C57BL/10SnPh (<italic>H2</italic><sup><italic>b</italic></sup>) or BALB/cHeA (<italic>H2</italic><sup><italic>d</italic></sup>) mice, or by ConA. IFN&#x003b3; production in MLCs of individual (O20&#x000a0;&#x000d7;&#x000a0;OcB-9)F<sub>2</sub> mice stimulated by irradiated C57BL/10 splenocytes and genotyped for microsatellite markers revealed four IFN&#x003b3;-controlling loci (<italic>Cypr4-Cypr7</italic>), each of which is closely linked with one of the four <italic>Lynf</italic> loci and with a cluster of susceptibility genes for different tumors. This suggests that inherited differences in certain lymphocyte responses may modify their propensity to infiltrate tumors and their capacity to affect tumor growth.</p></abstract><kwd-group><title>Keywords</title><kwd>Genetic control of interferon &#x003b3; production</kwd><kwd>Gene mapping</kwd><kwd>Lymphocyte infiltration of tumors</kwd><kwd>Tumor susceptibility</kwd></kwd-group><custom-meta-wrap><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer-Verlag 2010</meta-value></custom-meta></custom-meta-wrap></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Introduction</title><p>Interaction between the immune system and cancer is one of the most important determinants of cancer growth, progression, and metastasis. The interconnected processes of innate and adaptive immunity co-determine the development of cancer from the very beginning, when acute inflammation tends to suppress and chronic inflammation to promote carcinogenesis [<xref ref-type="bibr" rid="CR1">1</xref>]. The interaction of adaptive immunity with cancer is less clear. It is a powerful agent in rejection of virally induced tumors [<xref ref-type="bibr" rid="CR2">2</xref>], but its effects on spontaneous and carcinogen-induced tumors are still subject of discussion [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR4">4</xref>]. Recently, however, in a number of human cancers it has been observed that presence of infiltrating CD3<sup>+</sup> T lymphocytes is a positive prognostic factor [<xref ref-type="bibr" rid="CR5">5</xref>], although in some studies their effect was mitigated by presence of T regulatory lymphocytes [<xref ref-type="bibr" rid="CR6">6</xref>]. This indicated a positive role of CD3<sup>+</sup> T lymphocytes in suppression of cancer. However, it is not known why infiltrating T lymphocytes are abundant in cancers of some patients but scarce in others. Although in the past decade, a large progress has been made in unravelling the sequence of molecular steps that participate in the passage of lymphocytes from blood circulation into tumor, and more than 60 different molecules (or closely related members of the same family) that facilitate and mediate lymphocyte traffic were identified [<xref ref-type="bibr" rid="CR7">7</xref>], differences in structure or expression of these molecules were not yet correlated with individual propensity to tumor infiltration.</p><p>To the contrary, a new insight into the regulation of lymphocyte infiltration in tumors has been provided by the observations that the presence of infiltrating lymphocytes in mouse lung tumors is pronounced in some strains but virtually absent in others [<xref ref-type="bibr" rid="CR8">8</xref>] and that this difference is controlled by four chromosomal loci designated <italic>Lynf1</italic>&#x02013;<italic>Lynf4</italic> (<italic>Lynf</italic>&#x000a0;=&#x000a0;Lymphocyte infiltration) that determine the presence of intra-tumoral infiltrating lymphocytes [<xref ref-type="bibr" rid="CR9">9</xref>] in a cross between strains O20/A and OcB-9/Dem. Surprisingly, none of the four <italic>Lynf</italic> loci (<italic>Lynf1</italic>&#x02014;chromosome 4; <italic>Lynf2</italic>&#x02014;chromosome 8; <italic>Lynf3</italic> and <italic>Lynf4</italic>&#x02014;chromosome 6) encoded any of set of &#x0003e;60 molecules that were reported to participate in migration of lymphocytes into tumors. Therefore, other processes than direct molecular interactions of lymphocyte and surrounding tissue may be the primary determinants of individual&#x02019;s propensity to lymphocyte infiltration of tumors.</p><p>Our previous data showed that genetic polymorphisms of the intensity of nonspecific inflammation-related activity of immunocytes are linked with cancer susceptibility genes. We defined previously two loci, <italic>Marif1</italic> controlling production of IL-12, TNF&#x003b1; and iNOS, and <italic>Marif2</italic> controlling production of TNF&#x003b1; and IL-12, by in vitro stimulated bone marrow-derived macrophages [<xref ref-type="bibr" rid="CR10">10</xref>], and two loci, <italic>Cinda3</italic> and <italic>Cinda5</italic>, controlling in vitro proliferative response of lymphocytes to cytokines IL-2 and IL-4 [<xref ref-type="bibr" rid="CR11">11</xref>]. <italic>Marif1</italic> and <italic>Cinda3</italic> are linked to each other and <italic>Cinda3</italic> is closely linked to <italic>Lynf1</italic> as well as the mouse lung cancer susceptibility loci <italic>Sluc6/Sluc21</italic> on chromosome 4. <italic>Marif2</italic> and <italic>Cinda5</italic> are linked to each other and to <italic>Lynf2</italic> as well as to the mouse lung cancer susceptibility locus <italic>Sluc20</italic> on chromosome 8. This suggests a possible functional connection between activation of immunocytes and capacity of tumor infiltration.</p><p>In the present study, we analysed the genetic control of production of another cytokine, IFN&#x003b3;, during in vitro reaction to major histocompatibility complex (MHC) alloantigens. The differences in the MHC antigens induce the strongest responses [<xref ref-type="bibr" rid="CR12">12</xref>]. But genetic disparity in minor alloantigens also modifies the alloresponse. Earlier studies found that some strong MLC-stimulations (<italic>Mls</italic>) antigens are coded by mouse <italic>Mtv</italic> (mammary tumor virus) [<xref ref-type="bibr" rid="CR13">13</xref>]; later studies revealed a broad spectrum of additional minor human antigens [<xref ref-type="bibr" rid="CR14">14</xref>]. Intensity of MLC-response to alloantigens is determined by two major factors&#x02014;the genetic disparity between the responding and stimulating cells and the genetically defined intrinsic capacity of the responding cells to react to the stimulus [<xref ref-type="bibr" rid="CR15">15</xref>&#x02013;<xref ref-type="bibr" rid="CR17">17</xref>].</p><p>Responder cells react to stimulator cells by proliferation and by cytokine production. We have studied the genetic basis of these two responses, using the recombinant congenic (RC) strains, which were developed for analysis of multigenically controlled biological processes [<xref ref-type="bibr" rid="CR18">18</xref>]. A series of RC strains is derived from two parental inbred strains: a &#x0201c;background&#x0201d; strain and a &#x0201c;donor&#x0201d; strain. Each of these RC strains contains a different subset of about 12.5% of genes from the parental donor strain and the remaining approximately 87.5% of background strain genes. The BALB/cHeA-c-STS/A (CcS) and O20/A-c-B10.O20/Dem (OcB) series of strains were used previously for analysis of alloantigen response. The strain distribution pattern of magnitude of proliferative response in MLR of individual RC strains to stimulator cells of four different strains was almost identical, indicating that differences in responsiveness, rather than the alloantigenic difference itself, determine the magnitude of the response, and that the responsiveness to different MHC alloantigens is largely controlled by the same genes [<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR20">20</xref>]. We have mapped previously two of these responsiveness genes, <italic>Alan1</italic> and <italic>Alan2</italic> (Alloantigen response 1, 2) located on chromosomes 17 and 4, respectively, that control differences in proliferative response to several alloantigens in CcS and OcB RC strains [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR17">17</xref>]. We have also shown that in the individual RCS the levels of proliferation and IL-2 production in MLR are not correlated, and therefore these two responses are under a different genetic control [<xref ref-type="bibr" rid="CR19">19</xref>].</p><p>In the present work we defined four loci, <italic>Cypr4</italic>&#x02013;<italic>Cypr7</italic> (<italic>Cypr</italic>&#x000a0;=&#x000a0;<italic>Cytokine production</italic>), that control IFN&#x003b3; production by responder cells in MLR. IFN&#x003b3; plays important role in immunity against infection, and it has been associated with a number of autoinflammatory and autoimmune diseases (reviewed in [<xref ref-type="bibr" rid="CR21">21</xref>]). IFN&#x003b3; has also multiple and diverse essential functions in immune response to cancer [<xref ref-type="bibr" rid="CR22">22</xref>&#x02013;<xref ref-type="bibr" rid="CR25">25</xref>]. For that reason, genetics of capacity of IFN&#x003b3; production may be important for a variety of biological reactions. Here we show that control of IFN&#x003b3; production is genetically linked to and possibly responsible for the control of intensity of lymphocyte infiltration in tumors and control of tumor growth and progression.</p></sec><sec id="Sec2" sec-type="materials|methods"><title>Materials and methods</title><sec id="Sec3"><title>Mice</title><p>Males and females of strains O20/A (abbrev. O20), OcB-9/Dem (abbrev. OcB-9) (both strains have the MHC haplotype <italic>H2</italic><sup><italic>pz</italic></sup>) and F<sub>2</sub> hybrids between O20 and OcB-9 came from P. Demant&#x02019;s breeding colony. The haplotype <italic>H2</italic><sup><italic>pz</italic></sup> is described in [<xref ref-type="bibr" rid="CR26">26</xref>]. The genetic composition of strain OcB-9 has been described in detail by Stassen and co-workers [<xref ref-type="bibr" rid="CR27">27</xref>]. When used for these experiments strain OcB-9 passed more than 31 generations of brother&#x02013;sister mating and was highly homozygous. C57BL/10SnPh (abbrev. B10) (<italic>H2</italic><sup><italic>b</italic></sup>) mice were from the Institute of Molecular Genetics (Prague). As the strains O20 and OcB-9 are MHC identical, all mixed lymphocyte reactions tested in this paper involved the same MHC incompatibility (<italic>H2</italic><sup><italic>pz</italic></sup>&#x02013;<italic>H2</italic><sup><italic>b</italic></sup>).</p></sec><sec id="Sec4"><title>Mixed lymphocyte culture</title><p>Spleen cells of O20, OcB-9, and of individual F<sub>2</sub> hybrid mice (6&#x000a0;&#x000d7;&#x000a0;10<sup>5</sup> cells per well) were mixed with 8&#x000a0;&#x000d7;&#x000a0;10<sup>5</sup> irradiated (3000 R) C57BL/10 stimulator cells in 800&#x000a0;&#x003bc;l in 24-well tissue culture plates in complete RPMI 1640 medium, respectively (Nunc, Roskilde, Denmark) [<xref ref-type="bibr" rid="CR28">28</xref>]. Supernatants were removed after 96&#x000a0;h incubation period and stored at &#x02212;70&#x000b0;C before use. Each day in a separate experiment 20 F<sub>2</sub> mice and appropriate controls (O20 and OcB-9 mice) were tested. In the experiments, comparing IFN&#x003b3;, IL-2, and IL-4 production by stimulated lymphocytes of strains O20 and OcB-9, supernatants were removed also 48 and 72&#x000a0;h after stimulation.</p></sec><sec id="Sec5"><title>Concanavalin A-stimulated cultures</title><p>Spleen cells (4&#x000a0;&#x000d7;&#x000a0;10<sup>5</sup> cells per well) were incubated in 800&#x000a0;&#x003bc;l in 24-well tissue culture plates in complete RPMI 1640 medium with 2.5&#x000a0;&#x003bc;g/ml ConA. Supernatants were collected after 24, 48, or 72&#x000a0;h of incubation and assayed for IFN&#x003b3; presence.</p></sec><sec id="Sec6"><title>Estimation of cytokine levels</title><p>Supernatants from MLR cultures were assayed for IFN&#x003b3;, IL-2, and IL-4 presence using the primary and secondary mAbs (R46A2, XMG1.2; JES6-1A11, JES6-5H4; 11B11, BVD6-24G2) and standards (mIFN&#x003b3;, mIL-2, and mIL-4) from BD Bioscience, San Jose, CA. Similarly, supernatants from ConA stimulated cultures were assayed for IFN&#x003b3;. The ELISA was performed using the conditions recommended by BD Bioscience. In brief, a 96-well flatbottom plate (Costar, Cambridge, MA) was coated with primary mAb at a concentration of 1&#x000a0;&#x003bc;g/ml in 0.1&#x000a0;M NaHCO<sub>3</sub> pH 8.2 and incubated overnight at 4&#x000b0;C. The plates were washed with PBS-Tween (Costar, Corning, NY) and incubated for 2&#x000a0;h with 200&#x000a0;&#x003bc;l of PBS 8% BSA. After washing, aliquots of supernatants were added to duplicate wells and incubated overnight at 4&#x000b0;C. Plates were washed again and biotin-labeled secondary mAb was added for 45&#x000a0;min. Plates were washed, followed by addition of horseradish peroxidase streptavidin (Vector Laboratories, Burlingame, CA). 2,2&#x02032;-azino-bis(3-ethylbenzthiazoline-6-sulfonic acid) (Sigma-Aldrich, St. Louis, MO) and peroxide were used as chromogen. Color reaction was stopped by sodium dodecyl sulfate (SDS) in <italic>N</italic>,<italic>N</italic>-dimethylformamide and plates were read at OD 405&#x000a0;nm and the IFN&#x003b3; levels were estimated by the ELISA reader Tecan and the curve fitter program KIM-E (Schoeller Pharma, Prague, Czech Republic) using least square nonlinear regression analysis. Sensitivity of detection of IFN&#x003b3;, IL-2, and IL-4 levels in supernatants was 32, 4, and 15&#x000a0;pg/ml, respectively.</p></sec><sec id="Sec7"><title>Genotyping of microsatellites by PCR</title><p>DNA was isolated from tails using a standard proteinase procedure. The strain OcB-9 differs from O20 by carrying B10.O20-derived segments at 10 chromosomes [<xref ref-type="bibr" rid="CR27">27</xref>]. These differential segments were typed in the F<sub>2</sub> hybrid mice using 15 microsatellite markers: D2Mit7, D2Mit56; D4Mit54; D6Mit31, D6Mit52; D7Mit12, D7Nds2; D8Mit3, D8Mit65; D10Mit12; D11Mit15; D16Mit130; D18Mit17; D19Mit3, D19Mit63. These markers were selected because they cover optimally the chromosomal segments at which the OcB-9 strain has genetic material from the B10.O20 strain. They carry different alleles in the two parental strains, the O20 allele (designated <italic>o</italic>), and the B10.O20 allele (designated <italic>b</italic>). PCR genotyping was performed as described [<xref ref-type="bibr" rid="CR29">29</xref>]. Briefly, amplification was performed with a MJ Research Thermal Cycler PTC 100 Model 96 (MJ Research, Watertown, MA) in a volume of 10&#x000a0;&#x003bc;l with 20&#x000a0;ng DNA, 0.23&#x000a0;&#x003bc;M of forward primer [&#x003b3;-<sup>32</sup>P]ATP end-labeled with T4 polynucleotide kinase (New England Biolabs, Schwalbach, Germany), 0.23&#x000a0;&#x003bc;M of reverse primer, 200&#x000a0;&#x003bc;M of each dNTP and 0.04 u Taq polymerase (GIBCO, Grand Island, NY) in a 96-well U-bottom microtiter plate (FALCON, Oxford, UK) with 1 cycle of 3&#x000a0;min at 94&#x000b0;C and 30 cycles of 30&#x000a0;s at 94&#x000b0;C, 1&#x000a0;min at 55&#x000b0;C and 1&#x000a0;min at 72&#x000b0;C and 1 cycle of 1&#x000a0;min at 55&#x000b0;C, 3&#x000a0;min at 72&#x000b0;C, and 1&#x000a0;min at 23&#x000b0;C. Each PCR product was mixed with 30&#x000a0;&#x003bc;l of loading buffer and electrophoresed in 6% acrylamide gels for 2&#x02013;2.5&#x000a0;h at 50&#x000a0;W. Gels were wrapped in Saran Wrap (Dow Chemicals Co., Midland, MI) and exposed to X-ray film X-OMAT AR (Kodak, Weesp, The Netherlands) for 1.5&#x02013;24&#x000a0;h at &#x02212;70&#x000b0;C.</p></sec><sec id="Sec8"><title>Statistical analysis</title><p>The role of genetic factors in IFN&#x003b3; production in MLR response was examined by analysis of variance [ANOVA, PROC GLM statement of the SAS 8.2 for Windows (SAS Institute, Cary, NC)]. The effect of each marker, sex, and experiment on IFN&#x003b3; level in supernatants was tested. Each individual marker and its interactions with other markers and sex or experiment were subjected to ANOVA. A backward elimination procedure [<xref ref-type="bibr" rid="CR30">30</xref>] was followed wherein the interaction of marker (or interaction) bearing the highest <italic>P</italic> value (if <italic>P</italic>&#x000a0;&#x0003e;&#x000a0;0.05) was eliminated first. The markers and interactions with <italic>P</italic> value smaller than 0.05 were pooled for the next round of ANOVA. The backward elimination procedure was repeated till the final set of significant markers and interactions was obtained. The <italic>P</italic> values (<italic>Pc</italic>&#x000a0;=&#x000a0;&#x003b1;<sub>T</sub>) were corrected according to Lander and Kruglyak [<xref ref-type="bibr" rid="CR31">31</xref>] using the formula:<disp-formula id="Equa"><tex-math id="M1">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym} 
\usepackage{amsfonts} 
\usepackage{amssymb} 
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{upgreek}
\setlength{\oddsidemargin}{-69pt}
\begin{document}$$ \alpha_{T} * \approx \left[ {C + 2\rho Gh(T)} \right]\alpha_{T} $$\end{document}</tex-math></disp-formula>with <italic>G</italic>&#x000a0;=&#x000a0;2&#x000a0;M (the length of the segregating part of the genome: 12.5% of 16&#x000a0;M); <italic>C</italic>&#x000a0;=&#x000a0;10 (number of chromosomes segregating in this cross); &#x003c1;&#x000a0;=&#x000a0;1.5 for F<sub>2</sub> hybrids; and <italic>h</italic>(<italic>T</italic>)&#x000a0;=&#x000a0;the observed statistics (<italic>F</italic> ratio).</p><p>IFN&#x003b3;, IL-2, and IL-4 production in MLR by cells of responder strains O20 and OcB-9 was compared by Mann&#x02013;Whitney <italic>U</italic> test (STATISTICA for Windows 5.0, StatSoft, Inc., Tulsa, OK).</p></sec></sec><sec id="Sec9" sec-type="results"><title>Results</title><sec id="Sec10"><title>Strain differences in proliferation and production of cytokines after stimulation with alloantigen or ConA</title><p>The proliferation of lymphocytes of the strain OcB-9 in MLC is higher than that of the MHC-identical strain O20 (both <italic>H2</italic><sup><italic>pz</italic></sup>) after stimulation with lymphocytes of strains with C57BL/10 (<italic>H2</italic><sup><italic>b</italic></sup>), BALB/cHeA (<italic>H2</italic><sup><italic>d</italic></sup>), and CBA (<italic>H2</italic><sup><italic>k</italic></sup>) that carry unrelated MHC haplotypes (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref> and Ref. <xref ref-type="bibr" rid="CR17">17</xref>). This indicates that strain OcB-9 has a higher propensity to respond to a variety of alloantigens than O20. The production of IFN&#x003b3; in MLC is also significantly higher by OcB-9 than by O20 responder cells when stimulated by C57BL/10 (<italic>H2</italic><sup><italic>b</italic></sup>) cells (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>a) and BALB/c (<italic>H2</italic><sup><italic>d</italic></sup>) cells, but it is low in both with weaker stimulators DBA (<italic>H2</italic><sup><italic>q</italic></sup>) and CBA (<italic>H2</italic><sup><italic>k</italic></sup>) (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>b). OcB-9 lymphocytes are also better producers of IFN&#x003b3; than O20 lymphocytes after stimulation with ConA (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>). In MLC with C57BL/10 stimulator cells, the production of IL-2 (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>a) but not of IL-4 (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>b) is higher by OcB-9 than O20 responder cells.<fig id="Fig1"><label>Fig.&#x000a0;1</label><caption><p>The MLC reactivity of O20, B10.O20, and OcB-9 strains. Proliferative response of spleen cells in RPMI medium only and stimulated by C57BL/10Sn (<italic>H2</italic><sup><italic>b</italic></sup>) (B10), BALB/c (<italic>H2</italic><sup><italic>d</italic></sup>), and CBA/Ph (<italic>H2</italic><sup><italic>k</italic></sup>) alloantigens. Spleen cells (1.5&#x000a0;&#x000d7;&#x000a0;10<sup>5</sup> cells per well) were mixed with 2&#x000a0;&#x000d7;&#x000a0;10<sup>5</sup> irradiated (3000 R) B10, BALB/c or CBA/Ph stimulator cells in 200&#x000a0;&#x003bc;l in 96-well tissue culture plates. [3H]-thymidine (0.5&#x000a0;&#x003bc;Ci/well) was added into the cultures for the last 6&#x000a0;h of the 96-h incubation period as described previously [<xref ref-type="bibr" rid="CR17">17</xref>]. The data show the mean&#x000a0;&#x000b1;&#x000a0;SE from three independent experiments. Reproduced with the kind permission from Ref. [<xref ref-type="bibr" rid="CR17">17</xref>]</p></caption><graphic position="anchor" xlink:href="262_2009_739_Fig1_HTML" id="MO2"/></fig><fig id="Fig2"><label>Fig.&#x000a0;2</label><caption><p><bold>a</bold> Comparison of concentration of IFN&#x003b3; in supernatants of the spleen cells of the strains OcB-9 and O20 after alloantigen stimulation. Spleen cells (6&#x000a0;&#x000d7;&#x000a0;10<sup>5</sup> cells per well) were mixed with 8&#x000a0;&#x000d7;&#x000a0;10<sup>5</sup> irradiated (3000 R) C57BL/10 stimulator cells in 800&#x000a0;&#x003bc;l in 24-well tissue culture plates. Cell supernatants were analyzed 48, 72, and 96&#x000a0;h after stimulation. Data summarize the result of 13 independent experiments. Both female and male mice were used in our analysis, but no influence of sex on strain difference was observed. The columns show the means&#x000a0;&#x000b1;&#x000a0;SE of IFN&#x003b3; concentration in ng/ml. <italic>Filled square</italic>: OcB-9, <italic>unfilled square</italic>: O20. <bold>b</bold> Comparison of concentration of IFN&#x003b3; in supernatants of the spleen cells of the strains OcB-9 and O20 after stimulation by C57BL/10Sn (<italic>H2</italic><sup><italic>b</italic></sup>), BALB/c (<italic>H2</italic><sup><italic>d</italic></sup>), CBA (<italic>H2</italic><sup><italic>k</italic></sup>), and DBA/1 (<italic>H2</italic><sup><italic>q</italic></sup>) alloantigens. Spleen cells (6&#x000a0;&#x000d7;&#x000a0;10<sup>5</sup> cells per well) were mixed with 8&#x000a0;&#x000d7;&#x000a0;10<sup>5</sup> irradiated (3000 R) C57BL/10Sn, BALB/c, CBA, or DBA/1 stimulator cells in 800&#x000a0;&#x003bc;l in 24-well tissue culture plates. Cell supernatants were analysed 72 and 96&#x000a0;h after stimulation. Data summarize the result of 13 independent experiments</p></caption><graphic position="anchor" xlink:href="262_2009_739_Fig2_HTML" id="MO3"/></fig><fig id="Fig3"><label>Fig.&#x000a0;3</label><caption><p>Comparison of concentration of IFN&#x003b3; in supernatants of the spleen cells of the strains OcB-9 and O20 after stimulation with 2.5&#x000a0;&#x003bc;g/ml ConA. To test IFN&#x003b3; concentration, 800&#x000a0;&#x003bc;l of spleen cells (4&#x000a0;&#x000d7;&#x000a0;10<sup>5</sup> cells per well) were incubated in 24-well tissue culture plates in complete RPMI 1640 medium with 2.5&#x000a0;&#x003bc;g/ml ConA. After 24, 48, or 72&#x000a0;h of incubation supernatants were collected and assayed for IFN&#x003b3; presence. The columns show the means&#x000a0;&#x000b1;&#x000a0;SE of IFN&#x003b3; concentration in ng/ml. Data summarize the result of four independent experiments. <italic>Square</italic>: OcB-9, <italic>unfilled square</italic>: O20</p></caption><graphic position="anchor" xlink:href="262_2009_739_Fig3_HTML" id="MO4"/></fig><fig id="Fig4"><label>Fig.&#x000a0;4</label><caption><p><bold>a</bold> Comparison of concentration of IL-2 in supernatants of the spleen cells of the strains OcB-9 and O20 after alloantigen stimulation. Spleen cells (6&#x000a0;&#x000d7;&#x000a0;10<sup>5</sup> cells per well) were mixed with 8&#x000a0;&#x000d7;&#x000a0;10<sup>5</sup> irradiated (3000 R) C57BL/10 stimulator cells in 800 &#x003bc;l in 24-well tissue culture plates. Cell supernatants were analysed 48, 72, and 96&#x000a0;h after stimulation. Data summarize the result of 13 independent experiments. Both female and male mice were used in our analysis, but no influence of sex on strain difference was observed. The columns show the means&#x000a0;&#x000b1;&#x000a0;SE of IL-2 concentration in ng/ml. <italic>Filled square</italic>: OcB-9, <italic>unfilled square</italic>: O20. <bold>b</bold> Comparison of concentration of IL-4 in supernatants of the spleen cells of the strains OcB-9 and O20 after alloantigen stimulation. Spleen cells (6&#x000a0;&#x000d7;&#x000a0;10<sup>5</sup> cells per well) were mixed with 8&#x000a0;&#x000d7;&#x000a0;10<sup>5</sup> irradiated (3000 R) C57BL/10 stimulator cells in 800&#x000a0;&#x003bc;l in 24-well tissue culture plates. Cell supernatants were analysed 48, 72, and 96&#x000a0;h after stimulation. Data summarize the result of 13 independent experiments. Both female and male mice were used in our analysis, but no influence of sex on strain difference was observed. The columns show the means&#x000a0;&#x000b1;&#x000a0;SE of IL-4 concentration in ng/ml. <italic>Filled square</italic>: OcB-9, <italic>unfilled square</italic>: O20</p></caption><graphic position="anchor" xlink:href="262_2009_739_Fig4_HTML" id="MO5"/></fig></p></sec><sec id="Sec11"><title>Detection of loci that control IFN&#x003b3; level in MLC</title><p>Supernatants of the spleen cells of the strain OcB-9 contain higher concentration of IFN&#x003b3; 96&#x000a0;h after stimulation with C57BL/10 cells than supernatants of spleen cells of strain O20 (<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.014) (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>a). We examined production of IFN&#x003b3; in 240 F<sub>2</sub> hybrids between the strains O20 and OcB-9. The strains O20 and OcB-9 differ in their genetic material at 10 chromosomes [<xref ref-type="bibr" rid="CR27">27</xref>]. These differential segments were typed in the F<sub>2</sub> hybrids mice using 15 microsatellite markers listed above.</p><p>Statistical analysis revealed four genetic loci that influence level of IFN&#x003b3; in supernatants of (O20xOcB-9)F<sub>2</sub> splenocytes stimulated by irradiated C57BL/10 cells. Two of these loci have individual effects, but the other two operate in mutual nonadditive interaction. Two loci, <italic>Cypr4</italic> (Cytokine production 4) linked to D6Mit31 (corrected <italic>P</italic> value&#x000a0;&#x0003c;&#x000a0;0.00717) and <italic>Cypr5</italic> linked to D6Mit52 (corrected <italic>P</italic> value&#x000a0;&#x0003c;&#x000a0;0.000257) have effect on IFN&#x003b3; production after alloantigen stimulation that is not influenced by interaction with other genes (main effects) (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). These loci have an opposite effect on the studied trait. The homozygosity for the O20 allele of <italic>Cypr4</italic> (<italic>oo</italic>) determines about twofold higher level of IFN&#x003b3; than the homozygosity of the B10.O20 allele (<italic>bb</italic>), whereas homozygosity for the O20 allele of <italic>Cypr5</italic> is associated with about two-and-half fold decrease level of this cytokine than the homozygosity of the B10.O20 allele. Influence of the experimental group was evident (<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;1.75&#x000a0;&#x000d7;&#x000a0;10<sup>&#x02212;24</sup>), but no significant interaction between experimental group and marker was observed.<table-wrap id="Tab1"><label>Table&#x000a0;1</label><caption><p>Effects of genotype at the loci <italic>Cypr4</italic> and <italic>Cypr5</italic> on the concentration of IFN&#x003b3; in supernatants of spleen cells of individual F<sub>2</sub> hybrids between OcB-9 and O20 stimulated by irradiated B10 splenocytes</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">Marker/locus</th><th align="left" colspan="3">Genotype</th><th align="left" rowspan="2"><italic>P</italic> value</th><th align="left" rowspan="2">Corrected <italic>P</italic></th></tr><tr><th align="left"><italic>oo</italic></th><th align="left"><italic>ob</italic></th><th align="left"><italic>bb</italic></th></tr></thead><tbody><tr><td align="left">D6Mit31 (<italic>Cypr4</italic>)</td><td align="left">7.74&#x000a0;&#x000b1;&#x000a0;0.60 (<italic>n</italic>&#x000a0;=&#x000a0;64)</td><td align="left">5.77&#x000a0;&#x000b1;&#x000a0;0.47 (<italic>n</italic>&#x000a0;=&#x000a0;105)</td><td align="left">3.78&#x000a0;&#x000b1;&#x000a0;0.69 (<italic>n</italic>&#x000a0;=&#x000a0;63)</td><td char="." align="char">0.000100</td><td char="." align="char">0.00717</td></tr><tr><td align="left">D6Mit52 (<italic>Cypr5</italic>)</td><td align="left">3.66&#x000a0;&#x000b1;&#x000a0;0.74 (<italic>n</italic>&#x000a0;=&#x000a0;55)</td><td align="left">5.09&#x000a0;&#x000b1;&#x000a0;0.47 (<italic>n</italic>&#x000a0;=&#x000a0;121)</td><td align="left">9.43&#x000a0;&#x000b1;&#x000a0;0.66 (<italic>n</italic>&#x000a0;=&#x000a0;63)</td><td char="." align="char">0.00000296</td><td char="." align="char">0.000257</td></tr></tbody></table><table-wrap-foot><p>The phenotypic values given for individual genotypes indicate mean and standard errors of the concentration of IFN&#x003b3; and (in <italic>brackets</italic>) the number of mice (for computations the measured values of IFN&#x003b3; in supernatants (ng/ml) were normalized by natural logarithm of (value&#x000a0;+&#x000a0;0.5) to the power of 0.005)</p></table-wrap-foot></table-wrap></p><p><italic>Cypr6</italic> influences IFN&#x003b3; level in interaction with <italic>Cypr7</italic> (corrected <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.00111). F<sub>2</sub> mice with homozygous B10.O20 (<italic>bb</italic>) alleles at <italic>Cypr6</italic> and O20 (<italic>oo</italic>) alleles at <italic>Cypr7</italic> or homozygous for B10.O20 allele at <italic>Cypr7</italic> and homozygous for O20 alleles in <italic>Cypr6</italic> produce approximately twice higher IFN&#x003b3; level in supernatants in alloantigen-stimulated spleen cells in comparison with other combinations of <italic>Cypr6</italic> and <italic>Cypr7</italic> O20 and B10.O20 alleles (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). The levels of IFN&#x003b3; seem to be negatively correlated with the intensity of lymphocyte infiltration, both in the strains and in comparable genotypes. The production of IFN&#x003b3; is higher in the strain OcB-9 than O20, while in O20 mice the numbers of intratumoral lymphocytes are higher than in OcB-9 [<xref ref-type="bibr" rid="CR8">8</xref>]. A similar negative correlation is seen also at locus level: IFN&#x003b3; levels at the three <italic>Cypr4</italic> genotypes are negatively correlated with lymphocyte infiltration scores at the corresponding genotypes [<xref ref-type="bibr" rid="CR9">9</xref>] of the co-localizing <italic>Lynf4</italic> locus: <italic>oo</italic>: IFN&#x003b3;&#x02014;7.74&#x000a0;ng/ml, infiltration score (IS)&#x02014;0.04; <italic>ob</italic>: IFN&#x003b3;&#x02014;5.77&#x000a0;ng/ml, (IS)&#x02014;0.39; <italic>bb</italic>: IFN&#x003b3;&#x02014;3.78&#x000a0;ng/ml, (IS)&#x02014;0.34. Allelic correlations within the other <italic>Cypr-Lynf</italic> could not be assessed, because these loci were defined by inter-locus interactions.<table-wrap id="Tab2"><label>Table&#x000a0;2</label><caption><p>Effects of genotype at the loci <italic>Cypr6</italic> and <italic>Cypr7</italic> on the concentration of IFN&#x003b3; in supernatants of spleen cells of F<sub>2</sub> hybrids between OcB-9 and O20 stimulated by irradiated B10 splenocytes</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2"/><th align="left" colspan="3">D8Mit3 <italic>(Cypr7)</italic></th></tr><tr><th align="left"><italic>oo</italic></th><th align="left"><italic>ob</italic></th><th align="left"><italic>bb</italic></th></tr></thead><tbody><tr><td align="left" colspan="4">D4Mit54 (<italic>Cypr6</italic>)</td></tr><tr><td align="left">&#x000a0;<italic>oo</italic></td><td char="&#x000b1;" align="char">5.57&#x000a0;&#x000b1;&#x000a0;1.89 (<italic>n</italic>&#x000a0;=&#x000a0;15)</td><td char="&#x000b1;" align="char">3.13&#x000a0;&#x000b1;&#x000a0;0.93 (<italic>n</italic>&#x000a0;=&#x000a0;29)</td><td char="&#x000b1;" align="char">10.64&#x000a0;&#x000b1;&#x000a0;1.57 (<italic>n</italic>&#x000a0;=&#x000a0;10)</td></tr><tr><td align="left">&#x000a0;<italic>ob</italic></td><td char="&#x000b1;" align="char">5.16&#x000a0;&#x000b1;&#x000a0;0.83 (<italic>n</italic>&#x000a0;=&#x000a0;31)</td><td char="&#x000b1;" align="char">5.66&#x000a0;&#x000b1;&#x000a0;0.55 (<italic>n</italic>&#x000a0;=&#x000a0;58)</td><td char="&#x000b1;" align="char">4.67&#x000a0;&#x000b1;&#x000a0;0.69 (<italic>n</italic>&#x000a0;=&#x000a0;33)</td></tr><tr><td align="left">&#x000a0;<italic>bb</italic></td><td char="&#x000b1;" align="char">9.06&#x000a0;&#x000b1;&#x000a0;1.38 (<italic>n</italic>&#x000a0;=&#x000a0;10)</td><td char="&#x000b1;" align="char">4.77&#x000a0;&#x000b1;&#x000a0;0.77 (<italic>n</italic>&#x000a0;=&#x000a0;28)</td><td char="&#x000b1;" align="char">4.61&#x000a0;&#x000b1;&#x000a0;0.85 (<italic>n</italic>&#x000a0;=&#x000a0;11)</td></tr></tbody></table><table-wrap-foot><p>The phenotypic values given for individual genotypes indicate mean and standard errors of the concentration of IFN&#x003b3; and (in <italic>brackets</italic>) the number of mice. (B10.O20 allele <italic>b</italic>, O20 allele <italic>o</italic>), <italic>P</italic> value&#x000a0;=&#x000a0;nominal <italic>P</italic> value, corrected <italic>P</italic>&#x000a0;=&#x000a0;<italic>P</italic> value corrected for total genome screen)</p><p><italic>P</italic> value&#x000a0;=&#x000a0;0.000189, corrected <italic>P</italic> value&#x000a0;=&#x000a0;0.00111</p></table-wrap-foot></table-wrap></p></sec></sec><sec id="Sec12" sec-type="discussion"><title>Discussion</title><p>In the present study, we demonstrate genetic linkage between in vitro production of IFN&#x003b3; and in vivo lymphocyte infiltration of tumors. Previously, we have shown that responder&#x02019;s genotype strongly influences various in vitro responses of lymphocytes to stimulation by allogeneic cells [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR17">17</xref>], anti-CD3 antibodies [<xref ref-type="bibr" rid="CR28">28</xref>], mitogens [<xref ref-type="bibr" rid="CR32">32</xref>], and cytokines [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR28">28</xref>]. Importantly, in MLC these differences in response were obvious in spite of identical MHC incompatibility. We have shown that these differences are controlled by several loci with quantitative additive effects, and that different components of a response, for example proliferation or production of different cytokines, are controlled by different genes. We observed that two genetic loci that control activation of macrophages [<xref ref-type="bibr" rid="CR10">10</xref>] and lymphocytes [<xref ref-type="bibr" rid="CR11">11</xref>] co-localize with the genes that control susceptibility to lung tumors. This suggested that the loci regulating activity of lymphocytes and macrophages in vitro could have also in vivo effect on tumor growth. The genetic analysis of production of IFN&#x003b3; by responder lymphocytes in allogeneic mixed lymphocyte cultures demonstrated four genetic loci with significant influence. We analyzed the difference in the phenotype of interferon production between the strain O20 and the RC strain OcB-9 that is in about 87.5% genes identical to O20, but received a random subset of about 12.5% of genes from the strain B10.O20 [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR27">27</xref>]. The genetic material obtained from B10.O20 is almost entirely contained in several contiguous chromosomal segments, mostly 10&#x02013;20&#x000a0;cM long. They were described previously [<xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR33">33</xref>] and are covered by 15 polymorphic microsatellite markers listed in &#x0201c;<xref rid="Sec2" ref-type="sec">Materials and methods</xref>&#x0201d; section. Thus, any genetic differences between these two strains must be controlled by a gene or genes located in one of these B10.O20-derived segments [<xref ref-type="bibr" rid="CR34">34</xref>]. It should be pointed out that the strains O20 and OcB-9 have identical MHC haplotype (<italic>H2</italic><sup><italic>pz</italic></sup>), so they respond to the same MHC incompatibility (<italic>H2</italic><sup><italic>b</italic></sup>) and any difference in the response must be host-related. The stimulation by non-MHC alloantigens is not a likely cause of the observed differences in production of IFN&#x003b3; between O20 and OcB-9, because the two strains have the same genotype at the strong stimulatory locus <italic>Mtv13</italic> (<italic>Mls1</italic>) [<xref ref-type="bibr" rid="CR27">27</xref>] and no other stimulators in MLC were described in the vicinity of the <italic>Cypr</italic> loci mapped here.</p><p>However, the higher production of IFN&#x003b3; by OcB-9 cells is not likely a mere consequence of a higher proliferative response. We measured proliferation in parallel MLCs of individual F<sub>2</sub> hybrid animals that were tested for IFN&#x003b3; production. We found in that population only one locus controlling the proliferation, <italic>Alan2</italic> [<xref ref-type="bibr" rid="CR17">17</xref>]. It is linked to a marker that is different from but relatively close (6&#x000a0;cM) to the marker identifying <italic>Cypr6</italic>, so the identity of the two loci is neither indicated nor ruled out. The other three loci (<italic>Cypr4</italic>, <italic>5</italic>, and <italic>7</italic>) were not linked to proliferative activity in MLR. This prevailing genetic independence of proliferation and IFN&#x003b3; production in MLC is similar to the extensively documented distinct genetic control of lymphocyte proliferation and IL-2 production in MLC [<xref ref-type="bibr" rid="CR19">19</xref>].</p><p>An unexpected feature of our data is the complete co-localization of the four newly detected loci <italic>Cypr</italic> controlling production of IFN&#x003b3; in mixed lymphocyte culture with the four <italic>Lynf</italic> loci that control infiltration of lymphocytes into tumors: <italic>Cypr4</italic>&#x02013;<italic>Lynf4</italic>; <italic>Cypr5</italic>&#x02013;<italic>Lynf3</italic>; <italic>Cypr6</italic>&#x02013;<italic>Lynf1</italic>; <italic>Cypr7</italic>&#x02013;<italic>Lynf2</italic>. This general <italic>Cypr-Lynf</italic> co-localization contrasts sharply with a complete lack of co-localization of <italic>Lynf</italic> loci with any genes encoding the more than 60 molecules that were either reported to participate in traffic of lymphocytes from the circulation to tumors or belong to the same family [<xref ref-type="bibr" rid="CR9">9</xref>]. This suggests that, contrary to the prevailing emphasis in the literature, the principal control of capacity of lymphocytes to infiltrate tumors might reside in the regulation of the processes of lymphocyte activation.</p><p>In addition, the four <italic>Cypr</italic> loci described here co-localize with or are linked to a number of loci that control susceptibility to or patterns of progression of a variety of tumors that were independently described by different groups (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>). <italic>Cypr4</italic> is linked to four such loci, <italic>Mmom1</italic>, <italic>Ots1</italic>, <italic>Pas1c</italic>, <italic>Skts11</italic>, <italic>Cypr5</italic> to one locus, <italic>Ltsd8</italic>, <italic>Cypr6</italic> to 15 loci (10 of them within 5&#x000a0;cM) <italic>Gct1, Ltsd4, Naad5, Nbl1, Pcts, Sluc6, Sluc21, Ssic1, Stmn1, Tlsr3</italic>, and <italic>Cypr7</italic> to 7 loci <italic>Dlc1, Ltq, Ltsd3, Mfhas1, Sluc20, Scc8, Poats1</italic>.<table-wrap id="Tab3"><label>Table&#x000a0;3</label><caption><p>Co-localization of the four <italic>Cypr</italic> loci with cancer susceptibility loci/genes</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Locus with border markers</th><th align="left">Marker</th><th align="left">cM</th><th align="left">Locus/Gene</th><th align="left">cM</th><th align="left">Reference</th></tr></thead><tbody><tr><td align="left">O20 (<italic>o</italic>)</td><td align="left">D6Mit29</td><td align="left">36.50</td><td align="left"><italic>Lynf4</italic> (Lymphocyte infiltration 4)</td><td char="." align="char">35.15</td><td align="left">[<xref ref-type="bibr" rid="CR9">9</xref>]</td></tr><tr><td align="left">B10 (<italic>b</italic>)</td><td align="left">D6Mit31</td><td align="left">38.50</td><td align="left"><italic>Skts11</italic> (skin tumor susceptibility 11)</td><td char="." align="char">36.50</td><td align="left">[<xref ref-type="bibr" rid="CR42">42</xref>]</td></tr><tr><td align="left"><bold><italic>Cypr4</italic></bold><bold>(</bold><bold><italic>b</italic></bold><bold>)</bold></td><td align="left">D6Mit31</td><td align="left">38.50</td><td align="left"><italic>Pas1c</italic> (pulmonary adenoma susceptibility 1c)</td><td char="." align="char">37.00</td><td align="left">[<xref ref-type="bibr" rid="CR43">43</xref>]</td></tr><tr><td align="left">B10 (<italic>b</italic>)</td><td align="left">D6Mit327</td><td align="left">46.50</td><td align="left"><italic>Mmom3</italic> (mammary modifier of <italic>Min3</italic>)</td><td char="." align="char">38.50</td><td align="left">[<xref ref-type="bibr" rid="CR44">44</xref>]</td></tr><tr><td align="left">O20 (<italic>o</italic>)</td><td align="left">D6Mit10</td><td align="left">48.70</td><td align="left"><italic>Ots1</italic> (ovarian teratoma susceptibility 1)</td><td char="." align="char">40.00</td><td align="left">[<xref ref-type="bibr" rid="CR45">45</xref>]</td></tr><tr><td align="left">O20 (<italic>o</italic>)</td><td align="left">D6Mit334</td><td align="left">60.75</td><td align="left"><italic>Ltsd8</italic> (lung tumor shape-determining 8)</td><td char="." align="char">61.20</td><td align="left">[<xref ref-type="bibr" rid="CR46">46</xref>]</td></tr><tr><td align="left">B10 (<italic>b</italic>)</td><td align="left">D6Mit256</td><td align="left">60.95</td><td align="left"><italic>Lynf3</italic> (Lymphocyte infiltration 3)</td><td char="." align="char">61.20</td><td align="left">[<xref ref-type="bibr" rid="CR9">9</xref>]</td></tr><tr><td align="left"><bold><italic>Cypr5</italic></bold><bold>(</bold><bold><italic>b</italic></bold><bold>)</bold></td><td align="left">D6Mit52</td><td align="left">61.40</td><td align="left"/><td char="." align="char"/><td align="left"/></tr><tr><td align="left">B10 (<italic>b</italic>)</td><td align="left">D6Mit370</td><td align="left">62.67</td><td align="left"/><td char="." align="char"/><td align="left"/></tr><tr><td align="left">O20 (<italic>o</italic>)</td><td align="left">D6Mit13</td><td align="left">63.60</td><td align="left"/><td char="." align="char"/><td align="left"/></tr><tr><td align="left">O20 (<italic>o</italic>)</td><td align="left">D4Mit37</td><td align="left">56.50</td><td align="left"><italic>Lci</italic> (liver cell immortalization)</td><td char="." align="char">57.50</td><td align="left">[<xref ref-type="bibr" rid="CR47">47</xref>]</td></tr><tr><td align="left">B10 (<italic>b</italic>)</td><td align="left">D4Mit11</td><td align="left">57.40</td><td align="left"><italic>Naad4</italic> (Neu associated allelic deletion 4)</td><td char="." align="char">57.40</td><td align="left">[<xref ref-type="bibr" rid="CR48">48</xref>]</td></tr><tr><td align="left" rowspan="12"><bold><italic>Cypr6</italic></bold><bold>(</bold><bold><italic>b</italic></bold><bold>)</bold></td><td align="left" rowspan="12">D4Mit54</td><td align="left" rowspan="12">66.00</td><td align="left"><italic>Ril3</italic> (radiation-induced leukemia sensitivity 3)</td><td char="." align="char">60.00</td><td align="left">[<xref ref-type="bibr" rid="CR49">49</xref>]</td></tr><tr><td align="left"><italic>Sluc21</italic> (susceptibility to lung cancer 21)</td><td char="." align="char">63.00</td><td align="left">[<xref ref-type="bibr" rid="CR30">30</xref>]</td></tr><tr><td align="left"><italic>Tlsr3</italic> (thymic lymphoma suppressor region 3)</td><td char="." align="char">63.10</td><td align="left">[<xref ref-type="bibr" rid="CR50">50</xref>]</td></tr><tr><td align="left"><italic>Stmn1</italic> (stathmin 1)</td><td char="." align="char">65.70</td><td align="left">[<xref ref-type="bibr" rid="CR51">51</xref>]</td></tr><tr><td align="left"><italic>Naad5</italic> (Neu associated allelic deletion 5)</td><td char="." align="char">66.00</td><td align="left">[<xref ref-type="bibr" rid="CR52">52</xref>]</td></tr><tr><td align="left"><italic>Ltsd4</italic> (lung tumor shape-determining 4)</td><td char="." align="char">67.00</td><td align="left">[<xref ref-type="bibr" rid="CR46">46</xref>]</td></tr><tr><td align="left"><italic>Sluc6</italic> (susceptibility to lung cancer 6)</td><td char="." align="char">67.00</td><td align="left">[<xref ref-type="bibr" rid="CR53">53</xref>]</td></tr><tr><td align="left"><italic>Lynf1</italic> (Lymphocyte infiltration 1)</td><td char="." align="char">67.00</td><td align="left">[<xref ref-type="bibr" rid="CR9">9</xref>]</td></tr><tr><td align="left"><italic>Ssic1</italic> (susceptibility to small intestinal cancer 1)</td><td char="." align="char">67.00</td><td align="left">[<xref ref-type="bibr" rid="CR54">54</xref>]</td></tr><tr><td align="left"><italic>Nbl1</italic> (neuroblastoma, suppression of tumorigenicity 1)</td><td char="." align="char">70.00</td><td align="left">[<xref ref-type="bibr" rid="CR55">55</xref>]</td></tr><tr><td align="left"><italic>Pcts</italic> (plasmacytoma susceptibility)</td><td char="." align="char">70.00</td><td align="left">[<xref ref-type="bibr" rid="CR56">56</xref>]</td></tr><tr><td align="left"><italic>Gct1</italic> (granulosa cell tumorigenesis 1)</td><td char="." align="char">71.00</td><td align="left">[<xref ref-type="bibr" rid="CR57">57</xref>]</td></tr><tr><td align="left">B10 (<italic>b</italic>)</td><td align="left">D4Mit342</td><td align="left">77.50</td><td align="left"><italic>Pctr2</italic> (plasmacytoma resistance 2)</td><td char="." align="char">73.50</td><td align="left">[<xref ref-type="bibr" rid="CR58">58</xref>]</td></tr><tr><td align="left">O20 (<italic>o</italic>)</td><td align="left">D4Mit59</td><td align="left">78.90</td><td align="left"><italic>Tlsr2</italic> (thymic lymphoma suppressor region 2)</td><td char="." align="char">76.60</td><td align="left">[<xref ref-type="bibr" rid="CR50">50</xref>]</td></tr><tr><td align="left" rowspan="3">O20 (<italic>o</italic>)</td><td align="left" rowspan="3">Markers start at 1&#x000a0;cM</td><td align="left" rowspan="3"/><td align="left"><italic>Scc8</italic> (colon tumor susceptibility 8)</td><td char="." align="char">4.0</td><td align="left">[<xref ref-type="bibr" rid="CR59">59</xref>]</td></tr><tr><td align="left"><italic>Poats1</italic> (post-ovarectomy adrenal tumor susceptibility 1)</td><td char="." align="char">8.0</td><td align="left">[<xref ref-type="bibr" rid="CR60">60</xref>]</td></tr><tr><td align="left"><italic>Ltsd3</italic> (lung tumor shape-determining 3)</td><td char="." align="char">10.00</td><td align="left">[<xref ref-type="bibr" rid="CR46">46</xref>]</td></tr><tr><td align="left">B10 (<italic>b</italic>)</td><td align="left">D8Mit155</td><td align="left">1.00</td><td align="left"><italic>Sluc20</italic> (susceptibility to lung cancer 20)</td><td char="." align="char">10.00</td><td align="left">[<xref ref-type="bibr" rid="CR30">30</xref>]</td></tr><tr><td align="left" rowspan="2"><bold><italic>Cypr7</italic></bold><bold>(</bold><bold><italic>b</italic></bold><bold>)</bold></td><td align="left" rowspan="2">D8Mit3</td><td align="left" rowspan="2">10.00</td><td align="left"><italic>Lynf2</italic> (lymphocyte infiltration 2)</td><td char="." align="char">10.00</td><td align="left">[<xref ref-type="bibr" rid="CR9">9</xref>]</td></tr><tr><td align="left"><italic>Mfhas1</italic> (malignant fibrous histiocytoma amplified sequence 1)</td><td char="." align="char">20.00</td><td align="left">[<xref ref-type="bibr" rid="CR61">61</xref>]</td></tr><tr><td align="left">B10 (<italic>b</italic>)</td><td align="left">D8Mit98</td><td align="left">28.00</td><td align="left"><italic>Dlc1</italic> (deleted in liver cancer 1)</td><td char="." align="char">21.00</td><td align="left">[<xref ref-type="bibr" rid="CR62">62</xref>]</td></tr><tr><td align="left">O20 (<italic>o</italic>)</td><td align="left">D8Mit66</td><td align="left">28.00</td><td align="left"><italic>Ltq</italic> (lung tumor QTL)</td><td char="." align="char">30.00</td><td align="left">[<xref ref-type="bibr" rid="CR63">63</xref>]</td></tr></tbody></table></table-wrap></p><p>IFN&#x003b3; has an important role in host defenses, in both innate and acquired immunity. IFN&#x003b3; is produced by many different cell types, such as by T cells, NK cells, NKT cells [<xref ref-type="bibr" rid="CR35">35</xref>] upon their stimulation by antigens or mitogens. Macrophages and other accessory cells, such as dendritic cells, besides having a boosting effect on IFN&#x003b3; production by resting T cells [<xref ref-type="bibr" rid="CR36">36</xref>] can themselves also produce large amounts of IFN&#x003b3; [<xref ref-type="bibr" rid="CR37">37</xref>]. The interaction of T cells with antigen-presenting cells results in the production of IL-1, which then activates the T cells to produce IL-2, which promotes the IFN&#x003b3; production [<xref ref-type="bibr" rid="CR38">38</xref>]. All IFN&#x003b3; inducers activate T cells either in a polyclonal (mitogen or antibodies) or a clonally restricted (antigen-specific) manner.</p><p>IFN&#x003b3; (class II interferon) mediates broad immune responses to pathogens. It binds to IFNGR1/IFNGR2 receptor complex and uses JAK1/JAK2/STAT1 signaling pathway (reviewed in [<xref ref-type="bibr" rid="CR39">39</xref>]). IFN&#x003b3; modulates the expression of major histocompatibility antigens on many different accessory cells, and thus stimulates interaction of these cells with T cells. Enhanced expression of class II antigens after IFN&#x003b3; treatment also takes place on cells of T and B lineage [<xref ref-type="bibr" rid="CR40">40</xref>]. In the nonlymphoid organs, increased MHC antigens are found mainly on capillary endothelial cells, on renal tubular cells and on bronchiolar epithelial cells.</p><p>The role IFN&#x003b3; in suppression of tumor growth has been known for long time and the extensive literature cannot be reviewed here. Availability of genetically modified mice allowed to demonstrate also the role of IFN&#x003b3; in various aspects of anti-tumor immune responses [<xref ref-type="bibr" rid="CR22">22</xref>&#x02013;<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR41">41</xref>]. In some tests, it has been shown that this role may differ in different mouse strains [<xref ref-type="bibr" rid="CR22">22</xref>]. The present data show not only a linkage between the four <italic>Cypr</italic> loci that control production of IFN&#x003b3;, but also an apparently negative correlation between the IFN&#x003b3; levels and intensity of infiltration, not only in the tested strains, but also when comparing different alleles. However, the statistical significance of this relationship is not clear. Moreover, we are comparing results of a short-term assay (production of IFN&#x003b3; in MLR) and a condition of long duration (intensity of lymphocyte infiltration in tumors). Before the responsible <italic>Cypr-Lynf</italic> genes are identified, it is difficult to assess, which of the multiple effects of IFN&#x003b3; on lymphocytes, other inflammatory cells, vasculature, and tumor cells modifies the level of infiltration. <italic>Cypr-Lynf</italic> congenic strains, currently under production, will create possibilities for more detailed studies of function of these genes.</p><p>The data presented here may be a suitable model for analysis of the potent modifying effects of infiltrating lymphocytes in human cancer. Although the mechanisms of the suppressive effects of lymphocyte infiltration on growth of human cancers are not known, it is interesting that there is an extensive genetic association between the four <italic>Cypr-Lynf</italic> loci and more than 20 loci controlling susceptibility to and progression of a variety of mouse tumors (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>). Each of the four <italic>Cypr/Lynf</italic> loci is linked to a number of susceptibility loci to various tumors including lung, skin, ovary, liver, mammary gland, lymphomas, leukemia, plasmacytoma, and histiocytoma. This multiplicity of tumor types affected by these loci/genes is compatible with a genetic effect that is not organ specific but possibly systemic, like control of effective immunosurveillance.</p><p>In conclusion, our data provide a novel link between genetic polymorphisms of regulation of lymphocyte activation and genetic variation in immunoregulation of tumor growth. Analysis of the genes involved and their human homologues may contribute to the understanding of individual predisposition to a high or low anti-tumor activity of lymphocytes and thus improve the decisions about personalized selection of appropriate therapies.</p></sec></body><back><ack><p>We thank Neelima Kakarlapudi for useful comments. This work was supported by Grant Agency of the Czech Academy of Sciences (Grant GA AV A500520606), by Ministry of Education of the Czech Republic (Project Grant LC 06009), Grant Agency of the Czech Republic (Grant 310/08/H077), and Academy of Sciences of the Czech Republic (Project Grant AVOZ50520514). P.D. and L.Q. are supported by Roswell Park Cancer Institute&#x02019;s Institutional Funds and by NIH-NCI Grant 1R01CA127162-01.</p><p><bold>Open Access</bold> This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.</p></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Visser</surname><given-names>KE</given-names></name><name><surname>Eichten</surname><given-names>A</given-names></name><name><surname>Coussens</surname><given-names>LM</given-names></name></person-group><article-title>Paradoxical roles of the immune system during cancer development</article-title><source>Nat Rev Cancer</source><year>2006</year><volume>6</volume><fpage>24</fpage><lpage>37</lpage><pub-id pub-id-type="doi">10.1038/nrc1782</pub-id></citation><citation citation-type="display-unstructured">de Visser KE, Eichten A, Coussens LM (2006) Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 6:24&#x02013;37 <pub-id pub-id-type="pmid">16397525</pub-id></citation></ref><ref id="CR2"><label>2.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Klein</surname><given-names>G</given-names></name><name><surname>Imreh</surname><given-names>S</given-names></name><name><surname>Zabarovsky</surname><given-names>ER</given-names></name></person-group><article-title>Why do we not all die of cancer at an early age?</article-title><source>Adv Cancer Res</source><year>2007</year><volume>98</volume><fpage>1</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1016/S0065-230X(06)98001-4</pub-id></citation><citation citation-type="display-unstructured">Klein G, Imreh S, Zabarovsky ER (2007) Why do we not all die of cancer at an early age? Adv Cancer Res 98:1&#x02013;16 <pub-id pub-id-type="pmid">17433906</pub-id></citation></ref><ref id="CR3"><label>3.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Smyth</surname><given-names>MJ</given-names></name><name><surname>Dunn</surname><given-names>GP</given-names></name><name><surname>Schreiber</surname><given-names>RD</given-names></name></person-group><article-title>Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity</article-title><source>Adv Immunol</source><year>2006</year><volume>90</volume><fpage>1</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1016/S0065-2776(06)90001-7</pub-id></citation><citation citation-type="display-unstructured">Smyth MJ, Dunn GP, Schreiber RD (2006) Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Adv Immunol 90:1&#x02013;50 <pub-id pub-id-type="pmid">16730260</pub-id></citation></ref><ref id="CR4"><label>4.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Willimsky</surname><given-names>G</given-names></name><name><surname>Blankenstein</surname><given-names>T</given-names></name></person-group><article-title>The adaptive immune response to sporadic cancer</article-title><source>Immunol Rev</source><year>2007</year><volume>220</volume><fpage>102</fpage><lpage>112</lpage><pub-id pub-id-type="doi">10.1111/j.1600-065X.2007.00578.x</pub-id></citation><citation citation-type="display-unstructured">Willimsky G, Blankenstein T (2007) The adaptive immune response to sporadic cancer. Immunol Rev 220:102&#x02013;112 <pub-id pub-id-type="pmid">17979842</pub-id></citation></ref><ref id="CR5"><label>5.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Galon</surname><given-names>J</given-names></name><name><surname>Costes</surname><given-names>A</given-names></name><name><surname>Sanchez-Cabo</surname><given-names>F</given-names></name><name><surname>Kirilovsky</surname><given-names>A</given-names></name><name><surname>Mlecnik</surname><given-names>B</given-names></name><name><surname>Lagorce-Pages</surname><given-names>C</given-names></name><name><surname>Tosolini</surname><given-names>M</given-names></name><name><surname>Camus</surname><given-names>M</given-names></name><name><surname>Berger</surname><given-names>A</given-names></name><name><surname>Wind</surname><given-names>P</given-names></name><name><surname>Zinzindohoue</surname><given-names>F</given-names></name><name><surname>Bruneval</surname><given-names>P</given-names></name><name><surname>Cugnenc</surname><given-names>PH</given-names></name><name><surname>Trajanoski</surname><given-names>Z</given-names></name><name><surname>Fridman</surname><given-names>WH</given-names></name><name><surname>Pages</surname><given-names>F</given-names></name></person-group><article-title>Type, density, and location of immune cells within human colorectal tumors predict clinical outcome</article-title><source>Science</source><year>2006</year><volume>313</volume><fpage>1960</fpage><lpage>1964</lpage><pub-id pub-id-type="doi">10.1126/science.1129139</pub-id></citation><citation citation-type="display-unstructured">Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, Tosolini M, Camus M, Berger A, Wind P, Zinzindohoue F, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH, Pages F (2006) Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313:1960&#x02013;1964 <pub-id pub-id-type="pmid">17008531</pub-id></citation></ref><ref id="CR6"><label>6.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bui</surname><given-names>JD</given-names></name><name><surname>Uppaluri</surname><given-names>R</given-names></name><name><surname>Hsieh</surname><given-names>CS</given-names></name><name><surname>Schreiber</surname><given-names>RD</given-names></name></person-group><article-title>Comparative analysis of regulatory and effector T cells in progressively growing versus rejecting tumors of similar origins</article-title><source>Cancer Res</source><year>2006</year><volume>66</volume><fpage>7301</fpage><lpage>7309</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-06-0556</pub-id></citation><citation citation-type="display-unstructured">Bui JD, Uppaluri R, Hsieh CS, Schreiber RD (2006) Comparative analysis of regulatory and effector T cells in progressively growing versus rejecting tumors of similar origins. Cancer Res 66:7301&#x02013;7309 <pub-id pub-id-type="pmid">16849580</pub-id></citation></ref><ref id="CR7"><label>7.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Q</given-names></name><name><surname>Wang</surname><given-names>WC</given-names></name><name><surname>Evans</surname><given-names>SS</given-names></name></person-group><article-title>Tumor microvasculature as a barrier to antitumor immunity</article-title><source>Cancer Immunol Immunother</source><year>2003</year><volume>52</volume><fpage>670</fpage><lpage>679</lpage><pub-id pub-id-type="doi">10.1007/s00262-003-0425-4</pub-id></citation><citation citation-type="display-unstructured">Chen Q, Wang WC, Evans SS (2003) Tumor microvasculature as a barrier to antitumor immunity. Cancer Immunol Immunother 52:670&#x02013;679 <pub-id pub-id-type="pmid">12920482</pub-id></citation></ref><ref id="CR8"><label>8.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Horlings</surname><given-names>H</given-names></name><name><surname>Demant</surname><given-names>P</given-names></name></person-group><article-title>Lung tumor location and lymphocyte infiltration in mice are genetically determined</article-title><source>Exp Lung Res</source><year>2005</year><volume>31</volume><fpage>513</fpage><lpage>525</lpage></citation><citation citation-type="display-unstructured">Horlings H, Demant P (2005) Lung tumor location and lymphocyte infiltration in mice are genetically determined. Exp Lung Res 31:513&#x02013;525 <pub-id pub-id-type="pmid">16019985</pub-id></citation></ref><ref id="CR9"><label>9.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kakarlapudi</surname><given-names>N</given-names></name><name><surname>Vernooy</surname><given-names>JH</given-names></name><name><surname>Quan</surname><given-names>L</given-names></name><name><surname>Fijneman</surname><given-names>RJ</given-names></name><name><surname>Demant</surname><given-names>P</given-names></name></person-group><article-title>Control of lymphocyte infiltration of lung tumors in mice by host&#x02019;s genes: mapping of four <italic>Lynf</italic> (lymphocyte infiltration) loci</article-title><source>Cancer Immunol Immunother</source><year>2008</year><volume>57</volume><fpage>217</fpage><lpage>225</lpage><pub-id pub-id-type="doi">10.1007/s00262-007-0367-3</pub-id></citation><citation citation-type="display-unstructured">Kakarlapudi N, Vernooy JH, Quan L, Fijneman RJ, Demant P (2008) Control of lymphocyte infiltration of lung tumors in mice by host&#x02019;s genes: mapping of four Lynf (lymphocyte infiltration) loci. Cancer Immunol Immunother 57:217&#x02013;225 <pub-id pub-id-type="pmid">17703301</pub-id></citation></ref><ref id="CR10"><label>10.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fijneman</surname><given-names>RJ</given-names></name><name><surname>Vos</surname><given-names>M</given-names></name><name><surname>Berkhof</surname><given-names>J</given-names></name><name><surname>Demant</surname><given-names>P</given-names></name><name><surname>Kraal</surname><given-names>G</given-names></name></person-group><article-title>Genetic analysis of macrophage characteristics as a tool to identify tumor susceptibility genes: mapping of three macrophage-associated risk inflammatory factors, <italic>marif1</italic>, <italic>marif2</italic>, and <italic>marif3</italic></article-title><source>Cancer Res</source><year>2004</year><volume>64</volume><fpage>3458</fpage><lpage>3464</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-03-3767</pub-id></citation><citation citation-type="display-unstructured">Fijneman RJ, Vos M, Berkhof J, Demant P, Kraal G (2004) Genetic analysis of macrophage characteristics as a tool to identify tumor susceptibility genes: mapping of three macrophage-associated risk inflammatory factors, marif1, marif2, and marif3. Cancer Res 64:3458&#x02013;3464 <pub-id pub-id-type="pmid">15150098</pub-id></citation></ref><ref id="CR11"><label>11.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lipoldov&#x000e1;</surname><given-names>M</given-names></name><name><surname>Havelkov&#x000e1;</surname><given-names>H</given-names></name><name><surname>Badalov&#x000e1;</surname><given-names>J</given-names></name><name><surname>Demant</surname><given-names>P</given-names></name></person-group><article-title>Novel loci controlling lymphocyte proliferative response to cytokines and their clustering with loci controlling autoimmune reactions, macrophage function and lung tumor susceptibility</article-title><source>Int J Cancer</source><year>2005</year><volume>114</volume><fpage>394</fpage><lpage>399</lpage><pub-id pub-id-type="doi">10.1002/ijc.20731</pub-id></citation><citation citation-type="display-unstructured">Lipoldov&#x000e1; M, Havelkov&#x000e1; H, Badalov&#x000e1; J, Demant P (2005) Novel loci controlling lymphocyte proliferative response to cytokines and their clustering with loci controlling autoimmune reactions, macrophage function and lung tumor susceptibility. Int J Cancer 114:394&#x02013;399 <pub-id pub-id-type="pmid">15551356</pub-id></citation></ref><ref id="CR12"><label>12.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bodmer</surname><given-names>WF</given-names></name><name><surname>Jones</surname><given-names>EA</given-names></name><name><surname>Barnstable</surname><given-names>CJ</given-names></name><name><surname>Bodmer</surname><given-names>JG</given-names></name></person-group><article-title>Genetics HLA: the major human histocompatibility system</article-title><source>Proc R Soc Lond B Biol Sci</source><year>1978</year><volume>202</volume><fpage>93</fpage><lpage>116</lpage><pub-id pub-id-type="doi">10.1098/rspb.1978.0059</pub-id></citation><citation citation-type="display-unstructured">Bodmer WF, Jones EA, Barnstable CJ, Bodmer JG (1978) Genetics HLA: the major human histocompatibility system. Proc R Soc Lond B Biol Sci 202:93&#x02013;116 <pub-id pub-id-type="pmid">27817</pub-id></citation></ref><ref id="CR13"><label>13.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Huber</surname><given-names>BT</given-names></name></person-group><article-title><italic>Mls</italic> genes and self-superantigens</article-title><source>Trends Genet</source><year>1992</year><volume>8</volume><fpage>399</fpage><lpage>402</lpage></citation><citation citation-type="display-unstructured">Huber BT (1992) Mls genes and self-superantigens. Trends Genet 8:399&#x02013;402 <pub-id pub-id-type="pmid">1332231</pub-id></citation></ref><ref id="CR14"><label>14.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Feng</surname><given-names>X</given-names></name><name><surname>Hui</surname><given-names>KM</given-names></name><name><surname>Younes</surname><given-names>HM</given-names></name><name><surname>Brickner</surname><given-names>AG</given-names></name></person-group><article-title>Targeting minor histocompatibility antigens in graft versus tumor or graft versus leukemia responses</article-title><source>Trends Immunol</source><year>2008</year><volume>29</volume><fpage>624</fpage><lpage>632</lpage><pub-id pub-id-type="doi">10.1016/j.it.2008.09.004</pub-id></citation><citation citation-type="display-unstructured">Feng X, Hui KM, Younes HM, Brickner AG (2008) Targeting minor histocompatibility antigens in graft versus tumor or graft versus leukemia responses. Trends Immunol 29:624&#x02013;632 <pub-id pub-id-type="pmid">18952501</pub-id></citation></ref><ref id="CR15"><label>15.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rychlikova</surname><given-names>M</given-names></name><name><surname>Demant</surname><given-names>P</given-names></name><name><surname>Ivanyi</surname><given-names>P</given-names></name></person-group><article-title>The mixed lymphocyte reaction in H-2K, H-2D, and non-H-2 incompatibility</article-title><source>Biomedicine</source><year>1973</year><volume>18</volume><fpage>401</fpage><lpage>407</lpage></citation><citation citation-type="display-unstructured">Rychlikova M, Demant P, Ivanyi P (1973) The mixed lymphocyte reaction in H-2K, H-2D, and non-H-2 incompatibility. Biomedicine 18:401&#x02013;407 <pub-id pub-id-type="pmid">4270937</pub-id></citation></ref><ref id="CR16"><label>16.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hol&#x000e1;n</surname><given-names>V</given-names></name><name><surname>Havelkov&#x000e1;</surname><given-names>H</given-names></name><name><surname>Krulov&#x000e1;</surname><given-names>M</given-names></name><name><surname>Demant</surname><given-names>P</given-names></name><name><surname>Lipoldov&#x000e1;</surname><given-names>M</given-names></name></person-group><article-title>A novel alloreactivity-controlling locus, <italic>Alan1</italic>, mapped to mouse chromosome 17</article-title><source>Immunogenetics</source><year>2000</year><volume>51</volume><fpage>755</fpage><lpage>757</lpage><pub-id pub-id-type="doi">10.1007/s002510000197</pub-id></citation><citation citation-type="display-unstructured">Hol&#x000e1;n V, Havelkov&#x000e1; H, Krulov&#x000e1; M, Demant P, Lipoldov&#x000e1; M (2000) A novel alloreactivity-controlling locus, Alan1, mapped to mouse chromosome 17. Immunogenetics 51:755&#x02013;757 <pub-id pub-id-type="pmid">10941849</pub-id></citation></ref><ref id="CR17"><label>17.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Havelkov&#x000e1;</surname><given-names>H</given-names></name><name><surname>Badalov&#x000e1;</surname><given-names>J</given-names></name><name><surname>Demant</surname><given-names>P</given-names></name><name><surname>Lipoldov&#x000e1;</surname><given-names>M</given-names></name></person-group><article-title>A new type of genetic regulation of allogeneic response. A novel locus on mouse chromosome 4, <italic>Alan2</italic> controls MLC reactivity to three different alloantigens: C57BL/10, BALB/c and CBA</article-title><source>Genes Immun</source><year>2000</year><volume>1</volume><fpage>483</fpage><lpage>487</lpage><pub-id pub-id-type="doi">10.1038/sj.gene.6363711</pub-id></citation><citation citation-type="display-unstructured">Havelkov&#x000e1; H, Badalov&#x000e1; J, Demant P, Lipoldov&#x000e1; M (2000) A new type of genetic regulation of allogeneic response. A novel locus on mouse chromosome 4, Alan2 controls MLC reactivity to three different alloantigens: C57BL/10, BALB/c and CBA. Genes Immun 1:483&#x02013;487 <pub-id pub-id-type="pmid">11197689</pub-id></citation></ref><ref id="CR18"><label>18.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Demant</surname><given-names>P</given-names></name><name><surname>Hart</surname><given-names>AA</given-names></name></person-group><article-title>Recombinant congenic strains&#x02014;a new tool for analyzing genetic traits determined by more than one gene</article-title><source>Immunogenetics</source><year>1986</year><volume>24</volume><fpage>416</fpage><lpage>422</lpage><pub-id pub-id-type="doi">10.1007/BF00377961</pub-id></citation><citation citation-type="display-unstructured">Demant P, Hart AA (1986) Recombinant congenic strains&#x02014;a new tool for analyzing genetic traits determined by more than one gene. Immunogenetics 24:416&#x02013;422 <pub-id pub-id-type="pmid">3793154</pub-id></citation></ref><ref id="CR19"><label>19.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Holan</surname><given-names>V</given-names></name><name><surname>Lipoldov&#x000e1;</surname><given-names>M</given-names></name><name><surname>Demant</surname><given-names>P</given-names></name></person-group><article-title>Identical genetic control of MLC reactivity to different MHC incompatibilities, independent of production of and response to IL-2</article-title><source>Immunogenetics</source><year>1996</year><volume>44</volume><fpage>27</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.1007/BF02602654</pub-id></citation><citation citation-type="display-unstructured">Holan V, Lipoldov&#x000e1; M, Demant P (1996) Identical genetic control of MLC reactivity to different MHC incompatibilities, independent of production of and response to IL-2. Immunogenetics 44:27&#x02013;35 <pub-id pub-id-type="pmid">8613140</pub-id></citation></ref><ref id="CR20"><label>20.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Havelkov&#x000e1;</surname><given-names>H</given-names></name><name><surname>Holan</surname><given-names>V</given-names></name><name><surname>Karnik</surname><given-names>L</given-names></name><name><surname>Lipoldov&#x000e1;</surname><given-names>M</given-names></name></person-group><article-title>Mouse model for analysis of non-MHC genes that influence allogeneic response: recombinant congenic strains of OcB/Dem series that carry identical <italic>H2</italic> locus</article-title><source>Central European Journal of Biology</source><year>2006</year><volume>1</volume><fpage>16</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.2478/s11535-006-0002-x</pub-id></citation><citation citation-type="display-unstructured">Havelkov&#x000e1; H, Holan V, Karnik L, Lipoldov&#x000e1; M (2006) Mouse model for analysis of non-MHC genes that influence allogeneic response: recombinant congenic strains of OcB/Dem series that carry identical H2 locus. Central European Journal of Biology 1:16&#x02013;28 </citation></ref><ref id="CR21"><label>21.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schoenborn</surname><given-names>JR</given-names></name><name><surname>Wilson</surname><given-names>CB</given-names></name></person-group><article-title>Regulation of interferon-gamma during innate and adaptive immune responses</article-title><source>Adv Immunol</source><year>2007</year><volume>96</volume><fpage>41</fpage><lpage>101</lpage><pub-id pub-id-type="doi">10.1016/S0065-2776(07)96002-2</pub-id></citation><citation citation-type="display-unstructured">Schoenborn JR, Wilson CB (2007) Regulation of interferon-gamma during innate and adaptive immune responses. Adv Immunol 96:41&#x02013;101 <pub-id pub-id-type="pmid">17981204</pub-id></citation></ref><ref id="CR22"><label>22.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Street</surname><given-names>SE</given-names></name><name><surname>Trapani</surname><given-names>JA</given-names></name><name><surname>MacGregor</surname><given-names>D</given-names></name><name><surname>Smyth</surname><given-names>MJ</given-names></name></person-group><article-title>Suppression of lymphoma and epithelial malignancies effected by interferon gamma</article-title><source>J Exp Med</source><year>2002</year><volume>196</volume><fpage>129</fpage><lpage>134</lpage><pub-id pub-id-type="doi">10.1084/jem.20020063</pub-id></citation><citation citation-type="display-unstructured">Street SE, Trapani JA, MacGregor D, Smyth MJ (2002) Suppression of lymphoma and epithelial malignancies effected by interferon gamma. J Exp Med 196:129&#x02013;134 <pub-id pub-id-type="pmid">12093877</pub-id></citation></ref><ref id="CR23"><label>23.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Enzler</surname><given-names>T</given-names></name><name><surname>Gillessen</surname><given-names>S</given-names></name><name><surname>Manis</surname><given-names>JP</given-names></name><name><surname>Ferguson</surname><given-names>D</given-names></name><name><surname>Fleming</surname><given-names>J</given-names></name><name><surname>Alt</surname><given-names>FW</given-names></name><name><surname>Mihm</surname><given-names>M</given-names></name><name><surname>Dranoff</surname><given-names>G</given-names></name></person-group><article-title>Deficiencies of GM-CSF and interferon gamma link inflammation and cancer</article-title><source>J Exp Med</source><year>2003</year><volume>197</volume><fpage>1213</fpage><lpage>1219</lpage><pub-id pub-id-type="doi">10.1084/jem.20021258</pub-id></citation><citation citation-type="display-unstructured">Enzler T, Gillessen S, Manis JP, Ferguson D, Fleming J, Alt FW, Mihm M, Dranoff G (2003) Deficiencies of GM-CSF and interferon gamma link inflammation and cancer. J Exp Med 197:1213&#x02013;1219 <pub-id pub-id-type="pmid">12732663</pub-id></citation></ref><ref id="CR24"><label>24.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Qin</surname><given-names>Z</given-names></name><name><surname>Kim</surname><given-names>HJ</given-names></name><name><surname>Hemme</surname><given-names>J</given-names></name><name><surname>Blankenstein</surname><given-names>T</given-names></name></person-group><article-title>Inhibition of methylcholanthrene-induced carcinogenesis by an interferon gamma receptor-dependent foreign body reaction</article-title><source>J Exp Med</source><year>2002</year><volume>195</volume><fpage>1479</fpage><lpage>1490</lpage><pub-id pub-id-type="doi">10.1084/jem.20011887</pub-id></citation><citation citation-type="display-unstructured">Qin Z, Kim HJ, Hemme J, Blankenstein T (2002) Inhibition of methylcholanthrene-induced carcinogenesis by an interferon gamma receptor-dependent foreign body reaction. J Exp Med 195:1479&#x02013;1490 <pub-id pub-id-type="pmid">12045246</pub-id></citation></ref><ref id="CR25"><label>25.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Blankenstein</surname><given-names>T</given-names></name></person-group><article-title>The role of tumor stroma in the interaction between tumor and immune system</article-title><source>Curr Opin Immunol</source><year>2005</year><volume>17</volume><fpage>180</fpage><lpage>186</lpage><pub-id pub-id-type="doi">10.1016/j.coi.2005.01.008</pub-id></citation><citation citation-type="display-unstructured">Blankenstein T (2005) The role of tumor stroma in the interaction between tumor and immune system. Curr Opin Immunol 17:180&#x02013;186 <pub-id pub-id-type="pmid">15766679</pub-id></citation></ref><ref id="CR26"><label>26.</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Klein</surname><given-names>J</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Lyon</surname><given-names>M</given-names></name><name><surname>Searle</surname><given-names>A</given-names></name></person-group><article-title>Immunologically important loci</article-title><source>Genetic variants and strains of the laboratory mouse</source><year>1989</year><publisher-loc>Oxford</publisher-loc><publisher-name>Oxford University Press</publisher-name></citation><citation citation-type="display-unstructured">Klein J (1989) Immunologically important loci. In: Lyon M, Searle A (eds) Genetic variants and strains of the laboratory mouse. Oxford University Press, Oxford </citation></ref><ref id="CR27"><label>27.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stassen</surname><given-names>AP</given-names></name><name><surname>Groot</surname><given-names>PC</given-names></name><name><surname>Eppig</surname><given-names>JT</given-names></name><name><surname>Demant</surname><given-names>P</given-names></name></person-group><article-title>Genetic composition of the recombinant congenic strains</article-title><source>Mamm Genome</source><year>1996</year><volume>7</volume><fpage>55</fpage><lpage>58</lpage><pub-id pub-id-type="doi">10.1007/s003359900013</pub-id></citation><citation citation-type="display-unstructured">Stassen AP, Groot PC, Eppig JT, Demant P (1996) Genetic composition of the recombinant congenic strains. Mamm Genome 7:55&#x02013;58 <pub-id pub-id-type="pmid">8903730</pub-id></citation></ref><ref id="CR28"><label>28.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lipoldov&#x000e1;</surname><given-names>M</given-names></name><name><surname>Kosarov&#x000e1;</surname><given-names>M</given-names></name><name><surname>Zajicov&#x000e1;</surname><given-names>A</given-names></name><name><surname>Hol&#x000e1;n</surname><given-names>V</given-names></name><name><surname>Hart</surname><given-names>AA</given-names></name><name><surname>Krulov&#x000e1;</surname><given-names>M</given-names></name><name><surname>Demant</surname><given-names>P</given-names></name></person-group><article-title>Separation of multiple genes controlling the T-cell proliferative response to IL-2 and anti-CD3 using recombinant congenic strains</article-title><source>Immunogenetics</source><year>1995</year><volume>41</volume><fpage>301</fpage><lpage>311</lpage><pub-id pub-id-type="doi">10.1007/BF00172155</pub-id></citation><citation citation-type="display-unstructured">Lipoldov&#x000e1; M, Kosarov&#x000e1; M, Zajicov&#x000e1; A, Hol&#x000e1;n V, Hart AA, Krulov&#x000e1; M, Demant P (1995) Separation of multiple genes controlling the T-cell proliferative response to IL-2 and anti-CD3 using recombinant congenic strains. Immunogenetics 41:301&#x02013;311 <pub-id pub-id-type="pmid">7721352</pub-id></citation></ref><ref id="CR29"><label>29.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dietrich</surname><given-names>W</given-names></name><name><surname>Katz</surname><given-names>H</given-names></name><name><surname>Lincoln</surname><given-names>SE</given-names></name><name><surname>Shin</surname><given-names>HS</given-names></name><name><surname>Friedman</surname><given-names>J</given-names></name><name><surname>Dracopoli</surname><given-names>NC</given-names></name><name><surname>Lander</surname><given-names>ES</given-names></name></person-group><article-title>A genetic map of the mouse suitable for typing intraspecific crosses</article-title><source>Genetics</source><year>1992</year><volume>131</volume><fpage>423</fpage><lpage>447</lpage></citation><citation citation-type="display-unstructured">Dietrich W, Katz H, Lincoln SE, Shin HS, Friedman J, Dracopoli NC, Lander ES (1992) A genetic map of the mouse suitable for typing intraspecific crosses. Genetics 131:423&#x02013;447 <pub-id pub-id-type="pmid">1353738</pub-id></citation></ref><ref id="CR30"><label>30.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tripodis</surname><given-names>N</given-names></name><name><surname>Hart</surname><given-names>AA</given-names></name><name><surname>Fijneman</surname><given-names>RJ</given-names></name><name><surname>Demant</surname><given-names>P</given-names></name></person-group><article-title>Complexity of lung cancer modifiers: mapping of thirty genes and twenty-five interactions in half of the mouse genome</article-title><source>J Natl Cancer Inst</source><year>2001</year><volume>93</volume><fpage>1484</fpage><lpage>1491</lpage><pub-id pub-id-type="doi">10.1093/jnci/93.19.1484</pub-id></citation><citation citation-type="display-unstructured">Tripodis N, Hart AA, Fijneman RJ, Demant P (2001) Complexity of lung cancer modifiers: mapping of thirty genes and twenty-five interactions in half of the mouse genome. J Natl Cancer Inst 93:1484&#x02013;1491 <pub-id pub-id-type="pmid">11584065</pub-id></citation></ref><ref id="CR31"><label>31.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lander</surname><given-names>E</given-names></name><name><surname>Kruglyak</surname><given-names>L</given-names></name></person-group><article-title>Genetic dissection of complex traits: guidelines for interpreting and reporting linkage results</article-title><source>Nat Genet</source><year>1995</year><volume>11</volume><fpage>241</fpage><lpage>247</lpage><pub-id pub-id-type="doi">10.1038/ng1195-241</pub-id></citation><citation citation-type="display-unstructured">Lander E, Kruglyak L (1995) Genetic dissection of complex traits: guidelines for interpreting and reporting linkage results. Nat Genet 11:241&#x02013;247 <pub-id pub-id-type="pmid">7581446</pub-id></citation></ref><ref id="CR32"><label>32.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kosarov&#x000e1;</surname><given-names>M</given-names></name><name><surname>Havelkov&#x000e1;</surname><given-names>H</given-names></name><name><surname>Krulov&#x000e1;</surname><given-names>M</given-names></name><name><surname>Demant</surname><given-names>P</given-names></name><name><surname>Lipoldov&#x000e1;</surname><given-names>M</given-names></name></person-group><article-title>The production of two Th2 cytokines, interleukin-4 and interleukin-10, is controlled independently by locus <italic>Cypr1</italic> and by loci <italic>Cypr2</italic> and <italic>Cypr3</italic>, respectively</article-title><source>Immunogenetics</source><year>1999</year><volume>49</volume><fpage>134</fpage><lpage>141</lpage><pub-id pub-id-type="doi">10.1007/s002510050472</pub-id></citation><citation citation-type="display-unstructured">Kosarov&#x000e1; M, Havelkov&#x000e1; H, Krulov&#x000e1; M, Demant P, Lipoldov&#x000e1; M (1999) The production of two Th2 cytokines, interleukin-4 and interleukin-10, is controlled independently by locus Cypr1 and by loci Cypr2 and Cypr3, respectively. Immunogenetics 49:134&#x02013;141 <pub-id pub-id-type="pmid">9887350</pub-id></citation></ref><ref id="CR33"><label>33.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Groot</surname><given-names>PC</given-names></name><name><surname>Moen</surname><given-names>CJ</given-names></name><name><surname>Dietrich</surname><given-names>W</given-names></name><name><surname>Stoye</surname><given-names>JP</given-names></name><name><surname>Lander</surname><given-names>ES</given-names></name><name><surname>Demant</surname><given-names>P</given-names></name></person-group><article-title>The recombinant congenic strains for analysis of multigenic traits: genetic composition</article-title><source>FASEB J</source><year>1992</year><volume>6</volume><fpage>2826</fpage><lpage>2835</lpage></citation><citation citation-type="display-unstructured">Groot PC, Moen CJ, Dietrich W, Stoye JP, Lander ES, Demant P (1992) The recombinant congenic strains for analysis of multigenic traits: genetic composition. FASEB J 6:2826&#x02013;2835 <pub-id pub-id-type="pmid">1634045</pub-id></citation></ref><ref id="CR34"><label>34.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Demant</surname><given-names>P</given-names></name></person-group><article-title>Cancer susceptibility in the mouse: genetics, biology and implications for human cancer</article-title><source>Nat Rev Genet</source><year>2003</year><volume>4</volume><fpage>721</fpage><lpage>734</lpage><pub-id pub-id-type="doi">10.1038/nrg1157</pub-id></citation><citation citation-type="display-unstructured">Demant P (2003) Cancer susceptibility in the mouse: genetics, biology and implications for human cancer. Nat Rev Genet 4:721&#x02013;734 <pub-id pub-id-type="pmid">12951573</pub-id></citation></ref><ref id="CR35"><label>35.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cui</surname><given-names>J</given-names></name><name><surname>Shin</surname><given-names>T</given-names></name><name><surname>Kawano</surname><given-names>T</given-names></name><name><surname>Sato</surname><given-names>H</given-names></name><name><surname>Kondo</surname><given-names>E</given-names></name><name><surname>Toura</surname><given-names>I</given-names></name><name><surname>Kaneko</surname><given-names>Y</given-names></name><name><surname>Koseki</surname><given-names>H</given-names></name><name><surname>Kanno</surname><given-names>M</given-names></name><name><surname>Taniguchi</surname><given-names>M</given-names></name></person-group><article-title>Requirement for Valpha14 NKT cells in IL-12-mediated rejection of tumors</article-title><source>Science</source><year>1997</year><volume>278</volume><fpage>1623</fpage><lpage>1626</lpage><pub-id pub-id-type="doi">10.1126/science.278.5343.1623</pub-id></citation><citation citation-type="display-unstructured">Cui J, Shin T, Kawano T, Sato H, Kondo E, Toura I, Kaneko Y, Koseki H, Kanno M, Taniguchi M (1997) Requirement for Valpha14 NKT cells in IL-12-mediated rejection of tumors. Science 278:1623&#x02013;1626 <pub-id pub-id-type="pmid">9374462</pub-id></citation></ref><ref id="CR36"><label>36.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Blanchard</surname><given-names>DK</given-names></name><name><surname>Djeu</surname><given-names>JY</given-names></name><name><surname>Klein</surname><given-names>TW</given-names></name><name><surname>Friedman</surname><given-names>H</given-names></name><name><surname>Stewart</surname><given-names>WE</given-names><suffix>2nd</suffix></name></person-group><article-title>Interferon-gamma induction by lipopolysaccharide: dependence on interleukin 2 and macrophages</article-title><source>J Immunol</source><year>1986</year><volume>136</volume><fpage>963</fpage><lpage>970</lpage></citation><citation citation-type="display-unstructured">Blanchard DK, Djeu JY, Klein TW, Friedman H, Stewart WE 2nd (1986) Interferon-gamma induction by lipopolysaccharide: dependence on interleukin 2 and macrophages. J Immunol 136:963&#x02013;970 <pub-id pub-id-type="pmid">2867114</pub-id></citation></ref><ref id="CR37"><label>37.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Murata</surname><given-names>Y</given-names></name><name><surname>Ohteki</surname><given-names>T</given-names></name><name><surname>Koyasu</surname><given-names>S</given-names></name><name><surname>Hamuro</surname><given-names>J</given-names></name></person-group><article-title>IFN-gamma and pro-inflammatory cytokine production by antigen-presenting cells is dictated by intracellular thiol redox status regulated by oxygen tension</article-title><source>Eur J Immunol</source><year>2002</year><volume>32</volume><fpage>2866</fpage><lpage>2873</lpage><pub-id pub-id-type="doi">10.1002/1521-4141(2002010)32:10&#x0003c;2866::AID-IMMU2866&#x0003e;3.0.CO;2-V</pub-id></citation><citation citation-type="display-unstructured">Murata Y, Ohteki T, Koyasu S, Hamuro J (2002) IFN-gamma and pro-inflammatory cytokine production by antigen-presenting cells is dictated by intracellular thiol redox status regulated by oxygen tension. Eur J Immunol 32:2866&#x02013;2873 <pub-id pub-id-type="pmid">12355439</pub-id></citation></ref><ref id="CR38"><label>38.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vilcek</surname><given-names>J</given-names></name><name><surname>Henriksen-Destefano</surname><given-names>D</given-names></name><name><surname>Siegel</surname><given-names>D</given-names></name><name><surname>Klion</surname><given-names>A</given-names></name><name><surname>Robb</surname><given-names>RJ</given-names></name><name><surname>Le</surname><given-names>J</given-names></name></person-group><article-title>Regulation of IFN-gamma induction in human peripheral blood cells by exogenous and endogenously produced interleukin 2</article-title><source>J Immunol</source><year>1985</year><volume>135</volume><fpage>1851</fpage><lpage>1856</lpage></citation><citation citation-type="display-unstructured">Vilcek J, Henriksen-Destefano D, Siegel D, Klion A, Robb RJ, Le J (1985) Regulation of IFN-gamma induction in human peripheral blood cells by exogenous and endogenously produced interleukin 2. J Immunol 135:1851&#x02013;1856 <pub-id pub-id-type="pmid">3926889</pub-id></citation></ref><ref id="CR39"><label>39.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sadler</surname><given-names>AJ</given-names></name><name><surname>Williams</surname><given-names>BR</given-names></name></person-group><article-title>Interferon-inducible antiviral effectors</article-title><source>Nat Rev Immunol</source><year>2008</year><volume>8</volume><fpage>559</fpage><lpage>568</lpage><pub-id pub-id-type="doi">10.1038/nri2314</pub-id></citation><citation citation-type="display-unstructured">Sadler AJ, Williams BR (2008) Interferon-inducible antiviral effectors. Nat Rev Immunol 8:559&#x02013;568 <pub-id pub-id-type="pmid">18575461</pub-id></citation></ref><ref id="CR40"><label>40.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>KJ</given-names></name><name><surname>Chaouat</surname><given-names>G</given-names></name><name><surname>Leiserson</surname><given-names>WM</given-names></name><name><surname>King</surname><given-names>J</given-names></name><name><surname>Maeyer</surname><given-names>E</given-names></name></person-group><article-title>Characterization of T-cell-soluble factors modulating the expression of Ia and H-2 antigens on BALB/c B lymphoma cell lines</article-title><source>Cell Immunol</source><year>1983</year><volume>76</volume><fpage>253</fpage><lpage>267</lpage><pub-id pub-id-type="doi">10.1016/0008-8749(83)90368-4</pub-id></citation><citation citation-type="display-unstructured">Kim KJ, Chaouat G, Leiserson WM, King J, De Maeyer E (1983) Characterization of T-cell-soluble factors modulating the expression of Ia and H-2 antigens on BALB/c B lymphoma cell lines. Cell Immunol 76:253&#x02013;267 <pub-id pub-id-type="pmid">6404559</pub-id></citation></ref><ref id="CR41"><label>41.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kaplan</surname><given-names>DH</given-names></name><name><surname>Shankaran</surname><given-names>V</given-names></name><name><surname>Dighe</surname><given-names>AS</given-names></name><name><surname>Stockert</surname><given-names>E</given-names></name><name><surname>Aguet</surname><given-names>M</given-names></name><name><surname>Old</surname><given-names>LJ</given-names></name><name><surname>Schreiber</surname><given-names>RD</given-names></name></person-group><article-title>Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice</article-title><source>Proc Natl Acad Sci USA</source><year>1998</year><volume>95</volume><fpage>7556</fpage><lpage>7561</lpage><pub-id pub-id-type="doi">10.1073/pnas.95.13.7556</pub-id></citation><citation citation-type="display-unstructured">Kaplan DH, Shankaran V, Dighe AS, Stockert E, Aguet M, Old LJ, Schreiber RD (1998) Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci USA 95:7556&#x02013;7561 <pub-id pub-id-type="pmid">9636188</pub-id></citation></ref><ref id="CR42"><label>42.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nagase</surname><given-names>H</given-names></name><name><surname>Mao</surname><given-names>JH</given-names></name><name><surname>Balmain</surname><given-names>A</given-names></name></person-group><article-title>Allele-specific Hras mutations and genetic alterations at tumor susceptibility loci in skin carcinomas from interspecific hybrid mice</article-title><source>Cancer Res</source><year>2003</year><volume>63</volume><fpage>4849</fpage><lpage>4853</lpage></citation><citation citation-type="display-unstructured">Nagase H, Mao JH, Balmain A (2003) Allele-specific Hras mutations and genetic alterations at tumor susceptibility loci in skin carcinomas from interspecific hybrid mice. Cancer Res 63:4849&#x02013;4853 <pub-id pub-id-type="pmid">12941805</pub-id></citation></ref><ref id="CR43"><label>43.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Festing</surname><given-names>MF</given-names></name><name><surname>Lin</surname><given-names>L</given-names></name><name><surname>Devereux</surname><given-names>TR</given-names></name><name><surname>Gao</surname><given-names>F</given-names></name><name><surname>Yang</surname><given-names>A</given-names></name><name><surname>Anna</surname><given-names>CH</given-names></name><name><surname>White</surname><given-names>CM</given-names></name><name><surname>Malkinson</surname><given-names>AM</given-names></name><name><surname>You</surname><given-names>M</given-names></name></person-group><article-title>At least four loci and gender are associated with susceptibility to the chemical induction of lung adenomas in A/J&#x000a0;&#x000d7;&#x000a0;BALB/c mice</article-title><source>Genomics</source><year>1998</year><volume>53</volume><fpage>129</fpage><lpage>136</lpage><pub-id pub-id-type="doi">10.1006/geno.1998.5450</pub-id></citation><citation citation-type="display-unstructured">Festing MF, Lin L, Devereux TR, Gao F, Yang A, Anna CH, White CM, Malkinson AM, You M (1998) At least four loci and gender are associated with susceptibility to the chemical induction of lung adenomas in A/J&#x000a0;&#x000d7;&#x000a0;BALB/c mice. Genomics 53:129&#x02013;136 <pub-id pub-id-type="pmid">9790761</pub-id></citation></ref><ref id="CR44"><label>44.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Teske</surname><given-names>D</given-names></name><name><surname>Tess</surname><given-names>A</given-names></name><name><surname>Kohlhepp</surname><given-names>R</given-names></name><name><surname>Choi</surname><given-names>Y</given-names></name><name><surname>Kendziorski</surname><given-names>C</given-names></name><name><surname>Moser</surname><given-names>AR</given-names></name></person-group><article-title>Identification of novel modifier loci of Apc Min affecting mammary tumor development</article-title><source>Cancer Res</source><year>2007</year><volume>67</volume><fpage>11226</fpage><lpage>11233</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-07-2487</pub-id></citation><citation citation-type="display-unstructured">Wang H, Teske D, Tess A, Kohlhepp R, Choi Y, Kendziorski C, Moser AR (2007) Identification of novel modifier loci of Apc Min affecting mammary tumor development. Cancer Res 67:11226&#x02013;11233 <pub-id pub-id-type="pmid">18056448</pub-id></citation></ref><ref id="CR45"><label>45.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>GH</given-names></name><name><surname>Bugni</surname><given-names>JM</given-names></name><name><surname>Obata</surname><given-names>M</given-names></name><name><surname>Nishimori</surname><given-names>H</given-names></name><name><surname>Ogawa</surname><given-names>K</given-names></name><name><surname>Drinkwater</surname><given-names>NR</given-names></name></person-group><article-title>Genetic dissection of susceptibility to murine ovarian teratomas that originate from parthenogenetic oocytes</article-title><source>Cancer Res</source><year>1997</year><volume>57</volume><fpage>590</fpage><lpage>593</lpage></citation><citation citation-type="display-unstructured">Lee GH, Bugni JM, Obata M, Nishimori H, Ogawa K, Drinkwater NR (1997) Genetic dissection of susceptibility to murine ovarian teratomas that originate from parthenogenetic oocytes. Cancer Res 57:590&#x02013;593 <pub-id pub-id-type="pmid">9044831</pub-id></citation></ref><ref id="CR46"><label>46.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tripodis</surname><given-names>N</given-names></name><name><surname>Demant</surname><given-names>P</given-names></name></person-group><article-title>Genetic analysis of three-dimensional shape of mouse lung tumors reveals eight lung tumor shape-determining (<italic>Ltsd</italic>) loci that are associated with tumor heterogeneity and symmetry</article-title><source>Cancer Res</source><year>2003</year><volume>67</volume><fpage>125</fpage><lpage>131</lpage></citation><citation citation-type="display-unstructured">Tripodis N, Demant P (2003) Genetic analysis of three-dimensional shape of mouse lung tumors reveals eight lung tumor shape-determining (Ltsd) loci that are associated with tumor heterogeneity and symmetry. Cancer Res 63:125&#x02013;131 <pub-id pub-id-type="pmid">12517788</pub-id></citation></ref><ref id="CR47"><label>47.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>GH</given-names></name><name><surname>Ogawa</surname><given-names>K</given-names></name><name><surname>Nishimori</surname><given-names>H</given-names></name><name><surname>Drinkwater</surname><given-names>NR</given-names></name></person-group><article-title>Most liver epithelial cell lines from C3B6F1 mice exhibit parentally-biased loss of heterozygosity at the <italic>Lci</italic> (Liver cell immortalization) locus on chromosome 4</article-title><source>Oncogene</source><year>1995</year><volume>11</volume><fpage>2281</fpage><lpage>2287</lpage></citation><citation citation-type="display-unstructured">Lee GH, Ogawa K, Nishimori H, Drinkwater NR (1995) Most liver epithelial cell lines from C3B6F1 mice exhibit parentally-biased loss of heterozygosity at the Lci (Liver cell immortalization) locus on chromosome 4. Oncogene 11:2281&#x02013;2287 <pub-id pub-id-type="pmid">8570178</pub-id></citation></ref><ref id="CR48"><label>48.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cool</surname><given-names>M</given-names></name><name><surname>Depault</surname><given-names>F</given-names></name><name><surname>Jolicoeur</surname><given-names>P</given-names></name></person-group><article-title>Fine allelotyping of <italic>Erbb2</italic>-induced mammary tumors in mice reveals multiple discontinuous candidate regions of tumor-suppressor loci</article-title><source>Genes Chromosomes Cancer</source><year>2006</year><volume>45</volume><fpage>191</fpage><lpage>202</lpage><pub-id pub-id-type="doi">10.1002/gcc.20276</pub-id></citation><citation citation-type="display-unstructured">Cool M, Depault F, Jolicoeur P (2006) Fine allelotyping of Erbb2-induced mammary tumors in mice reveals multiple discontinuous candidate regions of tumor-suppressor loci. Genes Chromosomes Cancer 45:191&#x02013;202 <pub-id pub-id-type="pmid">16258954</pub-id></citation></ref><ref id="CR49"><label>49.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Meruelo</surname><given-names>D</given-names></name><name><surname>Offer</surname><given-names>M</given-names></name><name><surname>Flieger</surname><given-names>N</given-names></name></person-group><article-title>Genetics of susceptibility for radiation-induced leukemia. Mapping of genes involved to chromosomes 1, 2, and 4, and implications for a viral etiology in the disease</article-title><source>J Exp Med</source><year>1981</year><volume>154</volume><fpage>1201</fpage><lpage>1211</lpage><pub-id pub-id-type="doi">10.1084/jem.154.4.1201</pub-id></citation><citation citation-type="display-unstructured">Meruelo D, Offer M, Flieger N (1981) Genetics of susceptibility for radiation-induced leukemia. Mapping of genes involved to chromosomes 1, 2, and 4, and implications for a viral etiology in the disease. J Exp Med 154:1201&#x02013;1211 <pub-id pub-id-type="pmid">6270228</pub-id></citation></ref><ref id="CR50"><label>50.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Santos</surname><given-names>J</given-names></name><name><surname>Herranz</surname><given-names>M</given-names></name><name><surname>Perez de Castro</surname><given-names>I</given-names></name><name><surname>Pellicer</surname><given-names>A</given-names></name><name><surname>Fernandez-Piqueras</surname><given-names>J</given-names></name></person-group><article-title>A new candidate site for a tumor suppressor gene involved in mouse thymic lymphomagenesis is located on the distal part of chromosome 4</article-title><source>Oncogene</source><year>1998</year><volume>17</volume><fpage>925</fpage><lpage>929</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1202009</pub-id></citation><citation citation-type="display-unstructured">Santos J, Herranz M, Perez de Castro I, Pellicer A, Fernandez-Piqueras J (1998) A new candidate site for a tumor suppressor gene involved in mouse thymic lymphomagenesis is located on the distal part of chromosome 4. Oncogene
17:925&#x02013;929 <pub-id pub-id-type="pmid">9780010</pub-id></citation></ref><ref id="CR51"><label>51.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>XX</given-names></name><name><surname>Kozarsky</surname><given-names>K</given-names></name><name><surname>Strahler</surname><given-names>JR</given-names></name><name><surname>Eckerskorn</surname><given-names>C</given-names></name><name><surname>Lottspeich</surname><given-names>F</given-names></name><name><surname>Melhem</surname><given-names>R</given-names></name><name><surname>Lowe</surname><given-names>J</given-names></name><name><surname>Fox</surname><given-names>DA</given-names></name><name><surname>Hanash</surname><given-names>SM</given-names></name><name><surname>Atweh</surname><given-names>GF</given-names></name></person-group><article-title>Molecular cloning of a novel human leukemia-associated gene. Evidence of conservation in animal species</article-title><source>J Biol Chem</source><year>1989</year><volume>264</volume><fpage>14556</fpage><lpage>14560</lpage></citation><citation citation-type="display-unstructured">Zhu XX, Kozarsky K, Strahler JR, Eckerskorn C, Lottspeich F, Melhem R, Lowe J, Fox DA, Hanash SM, Atweh GF (1989) Molecular cloning of a novel human leukemia-associated gene. Evidence of conservation in animal species. J Biol Chem 264:14556&#x02013;14560 <pub-id pub-id-type="pmid">2760073</pub-id></citation></ref><ref id="CR52"><label>52.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cool</surname><given-names>M</given-names></name><name><surname>Jolicoeur</surname><given-names>P</given-names></name></person-group><article-title>Elevated frequency of loss of heterozygosity in mammary tumors arising in mouse mammary tumor virus/neu transgenic mice</article-title><source>Cancer Res</source><year>1999</year><volume>59</volume><fpage>2438</fpage><lpage>2444</lpage></citation><citation citation-type="display-unstructured">Cool M, Jolicoeur P (1999) Elevated frequency of loss of heterozygosity in mammary tumors arising in mouse mammary tumor virus/neu transgenic mice. Cancer Res 59:2438&#x02013;2444 <pub-id pub-id-type="pmid">10344755</pub-id></citation></ref><ref id="CR53"><label>53.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fijneman</surname><given-names>RJ</given-names></name><name><surname>Jansen</surname><given-names>RC</given-names></name><name><surname>van der Valk</surname><given-names>MA</given-names></name><name><surname>Demant</surname><given-names>P</given-names></name></person-group><article-title>High frequency of interactions between lung cancer susceptibility genes in the mouse: mapping of <italic>Sluc5</italic> to <italic>Sluc14</italic></article-title><source>Cancer Res</source><year>1998</year><volume>58</volume><fpage>4794</fpage><lpage>4798</lpage></citation><citation citation-type="display-unstructured">Fijneman RJ, Jansen RC, van der Valk MA, Demant P (1998) High frequency of interactions between lung cancer susceptibility genes in the mouse: mapping of Sluc5 to Sluc14. Cancer Res 58:4794&#x02013;4798 <pub-id pub-id-type="pmid">9809979</pub-id></citation></ref><ref id="CR54"><label>54.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fijneman</surname><given-names>RJ</given-names></name><name><surname>Demant</surname><given-names>P</given-names></name></person-group><article-title>A gene for susceptibility to small intestinal cancer, <italic>ssic1</italic>, maps to the distal part of mouse chromosome 4</article-title><source>Cancer Res</source><year>1995</year><volume>55</volume><fpage>3179</fpage><lpage>3182</lpage></citation><citation citation-type="display-unstructured">Fijneman RJ, Demant P (1995) A gene for susceptibility to small intestinal cancer, ssic1, maps to the distal part of mouse chromosome 4. Cancer Res 55:3179&#x02013;3182 <pub-id pub-id-type="pmid">7606739</pub-id></citation></ref><ref id="CR55"><label>55.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Matsuda</surname><given-names>Y</given-names></name><name><surname>Ozaki</surname><given-names>T</given-names></name><name><surname>Enomoto</surname><given-names>H</given-names></name><name><surname>Saito</surname><given-names>T</given-names></name><name><surname>Sakiyama</surname><given-names>S</given-names></name></person-group><article-title>Chromosome mapping of the mouse and rat homologs of the human <italic>DAN</italic> gene, D1S1733E</article-title><source>Mamm Genome</source><year>1996</year><volume>7</volume><fpage>709</fpage><lpage>710</lpage><pub-id pub-id-type="doi">10.1007/s003359900216</pub-id></citation><citation citation-type="display-unstructured">Matsuda Y, Ozaki T, Enomoto H, Saito T, Sakiyama S (1996) Chromosome mapping of the mouse and rat homologs of the human DAN gene, D1S1733E. Mamm Genome 7:709&#x02013;710 <pub-id pub-id-type="pmid">8703135</pub-id></citation></ref><ref id="CR56"><label>56.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mock</surname><given-names>BA</given-names></name><name><surname>Krall</surname><given-names>MM</given-names></name><name><surname>Dosik</surname><given-names>JK</given-names></name></person-group><article-title>Genetic mapping of tumor susceptibility genes involved in mouse plasmacytomagenesis</article-title><source>Proc Natl Acad Sci USA</source><year>1993</year><volume>90</volume><fpage>9499</fpage><lpage>9503</lpage><pub-id pub-id-type="doi">10.1073/pnas.90.20.9499</pub-id></citation><citation citation-type="display-unstructured">Mock BA, Krall MM, Dosik JK (1993) Genetic mapping of tumor susceptibility genes involved in mouse plasmacytomagenesis. Proc Natl Acad Sci USA 90:9499&#x02013;9503 <pub-id pub-id-type="pmid">8105477</pub-id></citation></ref><ref id="CR57"><label>57.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dorward</surname><given-names>AM</given-names></name><name><surname>Shultz</surname><given-names>KL</given-names></name><name><surname>Horton</surname><given-names>LG</given-names></name><name><surname>Li</surname><given-names>R</given-names></name><name><surname>Churchill</surname><given-names>GA</given-names></name><name><surname>Beamer</surname><given-names>WG</given-names></name></person-group><article-title>Distal Chr 4 harbors a genetic locus (<italic>Gct1</italic>) fundamental for spontaneous ovarian granulosa cell tumorigenesis in a mouse model</article-title><source>Cancer Res</source><year>2005</year><volume>65</volume><fpage>1259</fpage><lpage>1264</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-04-2992</pub-id></citation><citation citation-type="display-unstructured">Dorward AM, Shultz KL, Horton LG, Li R, Churchill GA, Beamer WG (2005) Distal Chr 4 harbors a genetic locus (Gct1) fundamental for spontaneous ovarian granulosa cell tumorigenesis in a mouse model. Cancer Res 65:1259&#x02013;1264 <pub-id pub-id-type="pmid">15735010</pub-id></citation></ref><ref id="CR58"><label>58.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bliskovsky</surname><given-names>V</given-names></name><name><surname>Ramsay</surname><given-names>ES</given-names></name><name><surname>Scott</surname><given-names>J</given-names></name><name><surname>DuBois</surname><given-names>W</given-names></name><name><surname>Shi</surname><given-names>W</given-names></name><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Qian</surname><given-names>X</given-names></name><name><surname>Lowy</surname><given-names>DR</given-names></name><name><surname>Mock</surname><given-names>BA</given-names></name></person-group><article-title>Frap, FKBP12 rapamycin-associated protein, is a candidate gene for the plasmacytoma resistance locus Pctr2 and can act as a tumor suppressor gene</article-title><source>Proc Natl Acad Sci USA</source><year>2003</year><volume>100</volume><fpage>14982</fpage><lpage>14987</lpage><pub-id pub-id-type="doi">10.1073/pnas.2431627100</pub-id></citation><citation citation-type="display-unstructured">Bliskovsky V, Ramsay ES, Scott J, DuBois W, Shi W, Zhang S, Qian X, Lowy DR, Mock BA (2003) Frap, FKBP12 rapamycin-associated protein, is a candidate gene for the plasmacytoma resistance locus Pctr2 and can act as a tumor suppressor gene. Proc Natl Acad Sci USA 100:14982&#x02013;14987 <pub-id pub-id-type="pmid">14634209</pub-id></citation></ref><ref id="CR59"><label>59.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>van Wezel</surname><given-names>T</given-names></name><name><surname>Ruivenkamp</surname><given-names>CA</given-names></name><name><surname>Stassen</surname><given-names>AP</given-names></name><name><surname>Moen</surname><given-names>CJ</given-names></name><name><surname>Demant</surname><given-names>P</given-names></name></person-group><article-title>Four new colon cancer susceptibility loci, <italic>Scc6 to Scc9</italic> in the mouse</article-title><source>Cancer Res</source><year>1999</year><volume>59</volume><fpage>4216</fpage><lpage>4218</lpage></citation><citation citation-type="display-unstructured">van Wezel T, Ruivenkamp CA, Stassen AP, Moen CJ, Demant P (1999) Four new colon cancer susceptibility loci, Scc6 to Scc9 in the mouse. Cancer Res 59:4216&#x02013;4218 <pub-id pub-id-type="pmid">10485458</pub-id></citation></ref><ref id="CR60"><label>60.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bernichtein</surname><given-names>S</given-names></name><name><surname>Petretto</surname><given-names>E</given-names></name><name><surname>Jamieson</surname><given-names>S</given-names></name><name><surname>Goel</surname><given-names>A</given-names></name><name><surname>Aitman</surname><given-names>TJ</given-names></name><name><surname>Mangion</surname><given-names>JM</given-names></name><name><surname>Huhtaniemi</surname><given-names>IT</given-names></name></person-group><article-title>Adrenal gland tumorigenesis after gonadectomy in mice is a complex genetic trait driven by epistatic loci</article-title><source>Endocrinology</source><year>2008</year><volume>149</volume><fpage>651</fpage><lpage>661</lpage><pub-id pub-id-type="doi">10.1210/en.2007-0925</pub-id></citation><citation citation-type="display-unstructured">Bernichtein S, Petretto E, Jamieson S, Goel A, Aitman TJ, Mangion JM, Huhtaniemi IT (2008) Adrenal gland tumorigenesis after gonadectomy in mice is a complex genetic trait driven by epistatic loci. Endocrinology 149:651&#x02013;661 <pub-id pub-id-type="pmid">18006632</pub-id></citation></ref><ref id="CR61"><label>61.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ko</surname><given-names>MS</given-names></name><name><surname>Kitchen</surname><given-names>JR</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Threat</surname><given-names>TA</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Hasegawa</surname><given-names>A</given-names></name><name><surname>Sun</surname><given-names>T</given-names></name><name><surname>Grahovac</surname><given-names>MJ</given-names></name><name><surname>Kargul</surname><given-names>GJ</given-names></name><name><surname>Lim</surname><given-names>MK</given-names></name><name><surname>Cui</surname><given-names>Y</given-names></name><name><surname>Sano</surname><given-names>Y</given-names></name><name><surname>Tanaka</surname><given-names>T</given-names></name><name><surname>Liang</surname><given-names>Y</given-names></name><name><surname>Mason</surname><given-names>S</given-names></name><name><surname>Paonessa</surname><given-names>PD</given-names></name><name><surname>Sauls</surname><given-names>AD</given-names></name><name><surname>DePalma</surname><given-names>GE</given-names></name><name><surname>Sharara</surname><given-names>R</given-names></name><name><surname>Rowe</surname><given-names>LB</given-names></name><name><surname>Eppig</surname><given-names>J</given-names></name><name><surname>Morrell</surname><given-names>C</given-names></name><name><surname>Doi</surname><given-names>H</given-names></name></person-group><article-title>Large-scale cDNA analysis reveals phased gene expression patterns during preimplantation mouse development</article-title><source>Development</source><year>2000</year><volume>127</volume><fpage>1737</fpage><lpage>1749</lpage></citation><citation citation-type="display-unstructured">Ko MS, Kitchen JR, Wang X, Threat TA, Wang X, Hasegawa A, Sun T, Grahovac MJ, Kargul GJ, Lim MK, Cui Y, Sano Y, Tanaka T, Liang Y, Mason S, Paonessa PD, Sauls AD, DePalma GE, Sharara R, Rowe LB, Eppig J, Morrell C, Doi H (2000) Large-scale cDNA analysis reveals phased gene expression patterns during preimplantation mouse development. Development 127:1737&#x02013;1749 <pub-id pub-id-type="pmid">10725249</pub-id></citation></ref><ref id="CR62"><label>62.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Durkin</surname><given-names>ME</given-names></name><name><surname>Avner</surname><given-names>MR</given-names></name><name><surname>Huh</surname><given-names>CG</given-names></name><name><surname>Yuan</surname><given-names>BZ</given-names></name><name><surname>Thorgeirsson</surname><given-names>SS</given-names></name><name><surname>Popescu</surname><given-names>NC</given-names></name></person-group><article-title>DLC-1, a Rho GTPase-activating protein with tumor suppressor function, is essential for embryonic development.</article-title><source>FEBS Lett</source><year>2005</year><volume>579</volume><fpage>1191</fpage><lpage>1196</lpage><pub-id pub-id-type="doi">10.1016/j.febslet.2004.12.090</pub-id></citation><citation citation-type="display-unstructured">Durkin ME, Avner MR, Huh CG, Yuan BZ, Thorgeirsson SS, Popescu NC (2005) DLC-1, a Rho GTPase-activating protein with tumor suppressor function, is essential for embryonic development. FEBS Lett 579:1191&#x02013;1196 <pub-id pub-id-type="pmid">15710412</pub-id></citation></ref><ref id="CR63"><label>63.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>D</given-names></name><name><surname>Lemon</surname><given-names>WJ</given-names></name><name><surname>You</surname><given-names>M</given-names></name></person-group><article-title>Linkage disequilibrium mapping of novel lung tumor susceptibility quantitative trait loci in mice</article-title><source>Oncogene</source><year>2002</year><volume>21</volume><fpage>6858</fpage><lpage>6865</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1205886</pub-id></citation><citation citation-type="display-unstructured">Wang D, Lemon WJ, You M (2002) Linkage disequilibrium mapping of novel lung tumor susceptibility quantitative trait loci in mice. Oncogene 21:6858&#x02013;6865 <pub-id pub-id-type="pmid">12360413</pub-id></citation></ref></ref-list><glossary><title>Abbreviations</title><def-list><def-item><term><italic>Cypr</italic></term><def><p>Cytokine production</p></def></def-item><def-item><term><italic>Lynf</italic></term><def><p>Lymphocyte infiltration</p></def></def-item><def-item><term>MLC</term><def><p>Mixed lymphocyte culture</p></def></def-item><def-item><term>MLR</term><def><p>Mixed lymphocyte reaction</p></def></def-item><def-item><term>QTL</term><def><p>Quantitative trait locus</p></def></def-item></def-list></glossary></back></article>


